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Abstract: 
Thalassemia is one of the most common genetically autosomal recessive disorders in the 
world as well as in Palestine.  There are more than 200 genetic mutations responsible for the 
decreased production of β-globin chain.  β-Thalassemia intermedia (βTI) is a type of 
thalassemia that lies between the two extreme transfusion dependent Thalassemia Major TM 
and transfusion independent Thalassemia Trait (TT). βTI shows a considerably variable 
clinical picture ranging from mild to severe anemia requiring occasional blood transfusion. 
Genetically, βTI is a heterogeneous group that is attributed to mutations in β-globin gene 
alone or co-inheritance of mutations in the β-globin gene and α- and/or γ-globin genes. The 
genetic determinants of βTI may be different in different regions and in particular in different 
ethnic groups and is affected by the different types of thalassemia alleles common in each 
area and ethnic group. We aimed to determine the spectrum of β- and α – globin gene 
mutations and Xmn I polymorphism of Gγ-globin gene in βTI patients in the West Bank 
region of Palestine as well as to evaluate the management practices of those patients.  A total 
of 51 cases of βTI were enrolled. Complete Blood Count (CBC) and Hb electrophoresis were 
evaluated. DNA sequencing was used to analyze β-globin gene mutations. Common α-globin 
gene mutations were screened by Gap-PCR (-α3.7, -α4.2, --MED, αααanti3.7) or DNA sequencing 
(α2-IVS II 5 nt del). Xmn I polymorphisms of Gγ-globin gene was determined by RFLP-PCR.  
Seven β-globin gene mutations were observed among the βTI patients, namely IVS-I -6 C>T, 
IVS-I-110 G>A, IVS-II-1 G>A, IVS-I-1 G>A, Codon 37 Trp>Stop, B -101 and IVS-II-848 
C>A. Ten genotypes were observed. Homozygosity for IVS-I-6 C>T accounted for the 
majority of βTI cases with a frequency of 74.5%. The second common β-globin gene 
genotype among study patients were homozygote IVS-I-110 G>A (5.8%) and homozygote 
IVS-II-1 G>A (5.8%). The remaining seven genotypes were each detected in about 2% of βTI 
patients. α-Thalassemia mutations were seen in five patients (9.8%), and included (-α3.7, 
αααanti3.7 and α2-IVSI 1-5 nt del). XmnI polymorphism of Gγ-globin gene was observed in 
four patients (7.84%), three homozygotes and one heterozygote for this SNP. The inheritance 
of the mild β-globin gene homozygote IVS-I-6 allele was the major contributing factor for the 
βTI phenotype among the study subjects. The role of Xmn I -158 C>T  SNP of Gγ-globin gene 
and α-thalassemia mutations in ameliorating the thalassemia phenotype was observed in few 
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patients for each factor.  In conclusion, homozygosity for β-globin gene mutation IVS-I-6 
C>T is the most common genotype among Palestinian βTI patients. The beta -101 C>T 
mutation was diagnosed in one patient in homozygote state for the first time in Palestine. The 
study results will positively affect the health management of βTI patients in Palestine and 
provide more data on the origin and distribution of β-globin gene alleles.  
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Chapter one   
 
Introduction 
 
1.1. Thalassemia  
Thalassemia is a genetic disorder characterized by inadequate synthesis of globin chain 
subunits of the hemoglobin (mostly α or β globin chains), while the globin chain is 
structurally normal. Thalassemia is classified into three different subclasses: thalassemia 
major (βTM)  the most severe form of thalassemia which is transfusion dependent, 
thalassemia intermedia (βTI) and the asymptomatic thalassemia trait (βTT)  (M. Karimi, 
Cohan, De Sanctis, Mallat, & Taher, 2014). 
Thalassemia is the most common autosomal recessive disorder in the world, especially in the 
Mediterranean, Middle-East, Transcaucasia, Central Asia, Indian subcontinent and Far East 
(Cao & Galanello, 2010). 
1.2. Beta Thalassemia Intermedia  
Beta-thalassemia intermedia (βTI) result from a group of heterogeneous mutations affecting 
the β-globin gene and the severity of the disorder can’t generally be predicted from the 
genotype. Some patients with βTI genotype are treated as thalassemia major because they 
present a relatively severe clinical disease, others may be classified as having thalassemia trait 
because of the asymptomatic or mild nature of their clinical condition (Cao & Galanello, 
2010). 
βTI shows a considerably variable clinical picture ranging from mild to severe anemia 
requiring occasional blood transfusion. Genetically, βTI is a heterogeneous group that is 
attributed to mutations in β-globin gene alone or co-inheritance of β-globin gene mutations 
and other globin genes such as α- or γ-globin genes. The genetic determinants of βTI may be 
different in different regions and in particular in different ethnic groups and is affected by the 
different types of thalassemia alleles common in each area and ethnic group. Fortunately, from 
the more than 200 mutations causing β-thalassemia, only less than 20 mutations are usually 
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responsible for the β-thalassemia in each specific ethnic group including 15 mutations that 
occur in the intervening sequences (Agouti et al., 2007). 
βTI was first described in 1955 by Rietti-Greppi-Micheli, where he used the term βTI to 
describe patients having less severe clinical courses than βTM and more severe courses than 
βTT by their phenotype and hematological tests.  βTI patients generally experience mild 
anemia with Hb level between 7-10 g/dl, survive well without regular transfusion, show 
normal growth development and generally onset of disease occurs between 2 and 6 years of 
age (Maria D. Cappellini, Musallam, & Taher, 2009; A. Taher, Isma'eel, & Cappellini, 2006). 
1.3. Clinical features of β thalassemia intermedia  
Patients with βTI show heterogeneous clinical picture. The clinical symptoms are pallor, 
extramedullary hematopoiesis, cholelithiasis, jaundice, leg ulcers; moderate to severe skeletal 
changes such as expansion of the facial bones and maxillary sinuses that causes protrusion of 
the upper jaw, more severe red blood cells morphology, hemolysis, hepatosplenomegally, 
osteoporosis and thrombotic complication. Patients also suffer from iron over load mainly 
from increased intestinal absorption of iron and the occasional blood transfusion (Maria D. 
Cappellini et al., 2009). 
 
1.3.1.   Extramedullary hematopoiesis (EMH) 
The ineffective red blood cell production from the bone marrow forces the hematopoietic 
tissue to expand outside the marrow and leads to hematopoietic compensatory mechanism. 
Most body organs are involved including the liver, spleen, lymph nodes, thymus, breasts, 
heart, kidneys, adrenal glands, prostate, pleura, skin, retroperitoneal tissue, cranial nerves and 
spinal canal. The incidence of extramedullary hematopoiesis in βTI patients reaches up to 20 
% compared with βTM that reaches < 1 %. The early diagnosis of EMH affects the course of 
management and reduces the irreversible neurologic damage. Magnetic resonance imaging 
(MRI)  is the method of choice for the diagnosis of EMH (Haidar, Mhaidli, & Taher, 2010) 
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1.3.2.   Pulmonary hypertension  
Pulmonary hypertension is a common complication in 59.1% of βTI patients and considered 
primary cause of congestive heart failure (CHF).  The mechanism causing pulmonary 
hypertension in βTI patients is unclear; but some evidences for the mechanism of pulmonary 
hypertension include; the endothelial dysfunction that increases the apoptosis and 
inflammation, pulmonary hemosiderosis, local thrombosis, decreased nitric oxide and nitric 
oxide synthase production. Pulmonary hypertension is reversible by blood transfusion and can 
be treated with aspirin and warfarin (A. Taher et al., 2006). 
 
1.3.3   Thrombophilia 
The βTI patients have a high risk of thrombosis compared with βTM, 4 % of βTI have a risk 
of thrombosis compared with 0.8% in βTM. Deep vein thrombosis (DVT), portal vein 
thrombosis, stroke and pulmonary embolism are the most common complications of 
thrombophilia. Splenectomized patients had higher incidence of thrombosis than non-
splenectomized patients; due to procoagulant activity of damaged circulating RBCs, where the 
RBC remnants expose negatively charged phosphatidyl-serine through the “Flip-Flop” 
phenomenon and initiate thrombosis (A. Taher et al., 2006). 
 
1.3.4      Endocrine diseases and pregnancy 
Osteoporosis due to bone marrow expansion and vitamin D deficiency are highly prevalent in 
βTI patients. Fertility is usually normal, delayed puberty is common, hypothyroidism and 
diabetes mellitus are rare (Musallam et al., 2011). 
Pregnant women with βTI have a high risk of abortion, pre-term delivery, caesarean delivery, 
thromboembolic events and intrauterine growth restriction. Splenomegaly interferes with the 
enlargement of uterus that may be complicated by hypersplenism and thus splenectomy is 
necessary after delivery as well as the administration of anticoagulant therapy (Nassar et al., 
2006). 
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1.3.5   Leg ulcers  
It is unclear why some patients of βTI develop leg ulcers. However it`s more common in 
elderly βTI patients than younger patients. The skin of the extremities is thin due to reduced 
tissue oxygenation that makes tissues fragile and increases the risk of ulcers.  These ulcers are 
indolent and painful. Keeping the patients leg above the level of the heart decreases the pain 
and can be beneficial (Musallam et al., 2011). 
 
1.3.6   Gallstones 
Gallstones are more common in βTI than βTM as a result of ineffective erythropoiesis and                                                 
hemolysis. Uridine 5`-diphospho-alpha-d-glucose (UDPG) deficiency increases the risk of 
gallstones formation. Cholecystectomy should be performed in symptomatic gallstones 
patients to prevent cholecystitis which is a serious problem in splenectomized patients (Maria 
D. Cappellini et al., 2009). 
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1.4 Molecular biology of βTI  
The β-globin gene is located on the short arm of chromosome 11 within the β-globin gene 
cluster. This region also contains δ-gene, embryonic gene (ε-gene) and the Aγ-gene, Gγ-gene, 
and the pseudogene (ψβ1) gene. While the α-globin gene cluster is located on chromosome 16 
(Figure 1). 
 
Figure 1.  The localization of β-and α-gene clusters on chromosomes 11 and 16, respectively 
(Cao & Galanello, 2010). 
 
The β-globin gene contains three exons and both the 5` and 3` untranslated region (UTRs), 
which spans 1.6 Kb. The gene is regulated by a 5` promoter that contains TATA, CAAT and 
duplicated CACCC boxes. A major regulatory region contains a strong enhancer that maps 
50Kb from the beta gene, this region contains the locus control region (LCR) that includes 
four HS sites (HS-1 to HS-4), and the erythroid specific DNase hypersensitivity sites (HSs) 
(Cao & Galanello, 2010). 
The majority of mutations causing β-thalassemia are single nucleotide substitutions or 
insertions of oligonucleotide that lead to frame shift or deletions.  Point mutations belong to 
three categories: mutations in the promoter and 5` UTR (defective gene transcription), 
mutations affecting the mRNA processing, and mutations that result in abnormal mRNA 
translation (Cao & Galanello, 2010). 
The genetic basis of βTI for phenotype diversity is explained by three terms primary, 
secondary, and tertiary.  The primary modifiers reflect the broad spectrum of mutations 
affecting the β-gene and range from mild promoter mutations (the slight reduction in β-gene 
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production) to many different mutations that result in β0-thalassemia.  The secondary 
modifiers include modifiers that make imbalance between the globin chains; the coinheritance 
of α-thalassemia has this effect, also the production of more γ-chains of fetal hemoglobin after 
birth.  The tertiary modifiers include those that are not related to globin chains but have 
important effects in the complications of the disease. Figure 2 represents several genetic 
profiles that lead to βTI phenotype (Musallam et al., 2011). 
 
Figure 2: Genetic profiles that may lead to thalassemia intermedia phenotype. HPFH: 
Hereditary persistence of fetal hemoglobin; Hb: hemoglobin (Musallam et al., 2011). 
 
The molecular basis of βTI can be classified into the following categories: 
 Homozygosity or compound heterozygosity for mild mutations. 
 Homozygosity or compound heterozygosity for severe mutations plus α-thlassemia or 
heterocellular HPFH 
 Compound heterozygosity for β-thalassemia and (δβ-thalassemia and deletion or non-
deletion HPFH) 
 Heterozygosity for β-thalassemia and triplicate α-locus (αααanti3.7) 
 Heterozygosity for a dominant form of β-thalassemia (Camaschella et al., 1995) 
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1.4.1   Homozygous β-thalassemia intermedia 
Portuguese thalassemia was the first description of mild thalassemia mutation due to the 
homozygosity of IVS-I-6 T>C mutation. This substitution creates alternative splice sites in 
vitro that produces a normal β chains; and it is mild mutation in vivo. Other mild mutations 
are -87 C>G and -101 C>T that are associated with decreased production of β-gene 
transcription (Camaschella et al., 1995). 
 
The most important mechanism of βTI is the coinheritance of homozygosity or compound 
heterozygosity for β-thalassemia alleles. The most common mutation in Mediterranean area is 
the mild mutation IVS-I-6 T>C and IVS-I-110 G>A.  Other mild mutations include the 
coinheritance of homozygous β-thalassemia with α-thalassemia by reducing the imbalance 
between alpha and beta chains.  Other mild mutations include the continuous production of 
gamma chain in adults, which reduces the imbalance between alpha and non-alpha chains, 
where the increase in gamma chain compensates for the decrease in beta chain and produces 
mild thalassemia (Cao & Galanello, 2010). 
 
1.4.2 Heterozygous β-thalassemia intermedia 
Heterozygous beta-thalassemia either beta+ or beta
0
 is asymptomatic and characterized by 
increased RBC count, microcytosis, hypochromia and increased HbA2 level. There are two 
mechanisms that may increase the severity of clinical and hematological manifestations.  The 
first mechanism includes; the co-inheritance of heterozygous beta globin gene mutation and 
triplicated or quadruplicated α-globin gene rearrangement which increases the imbalance 
between α-globin and non-α-globin chain synthesis.  The second is the presence of other 
mutations in the β-globin chain that cause instability of β-chains. Unstable β-globin chains 
bind to heme and precipitate in the red blood precursors before assembly with alpha chains 
and lead to production of inclusion bodies. Precipitation of defective β-chains occurs not only 
in mature erythrocytes but also in erythroblasts causing ineffective erythropoiesis (Agarwal, 
Sarwai, Agarwal, Gupta, & Phadke, 2002; Camaschella et al., 1995; Gasperini, Perseu, Melis, 
& Maccioni, 1998). 
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1.4.3   Interaction of α-globin gene triplication with β-globin gene  
The inheritance of α-thalassemia with β-thalassemia reduces the imbalance between alpha and 
beta gobin chain. The triplication of α-globin gene (αααanti 3.7) is due to unequal crossing over 
between misaligned homologous segments during meiosis in the globin gene cluster. The 
clinical and hematological phenotype may vary from mild anemia in case of (-α/αα) to severe 
anemia in case of (αα/ααα).   The coinheritance of αααanti 3.7 allele aggravates the mild β-
thalassemia carrier phenotype to βTI phenotype (Farashi et al., 2015). 
 
1.4.4    Mutations in γ-globin gene  
Continuous production of γ-globin chains is due to coinheritance of genetic determinants; 
which reduce the imbalance of alpha/non-alpha chains.  The increased production of gamma 
chains -196 CT A-gamma compensates for the absence of beta chain, compound 
heterozygosity for this determinants and beta thalassemia produces a βTI phenotype.  The -
158 C>T 
Gγ-globin gene is silent in normal subjects and heterozygote beta thalassemia but 
results in increased Hb F production due to hematopoietic stress. The   -158 C>T G-gamma 
SNP has been reported in association with IVS-II-I (GA), frame shift 8 (A. T. M. Taher, K. 
M. Karimi, M. El-Beshlawy, A. Belhoul, K. Daar, S. et al), frame shift 6 (-A), and codon 39 
nonsense mutations and this explains the mild phenotype with these mutations (Cao & 
Galanello, 2010). 
 
1.4.5   Novel mutations in the second intervening sequence  
Agouti et al have identified a thalassemia intermedia patient characterized by increased HbA2 
levels and increased HbF level with moderate anemia. This hematological phenotype is typical 
for homozygote or compound heterozygote for mild β+; but DNA sequencing revealed that 
this patient was homozygote for IVS-II-726 A>G substitution.  This mutation is responsible 
for the β+ phenotype.  This mutation creates a cryptic splice signal (normal splice junctions 
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and the cryptic splice sites not themselves changed) that is used as an alternative site to the 
existing sites (Agouti et al., 2007; Murru, 1991). 
 
1.4.6   New insertions/ frame shifts mutations 
Williamson et al, have studied a mild thalassemia intermedia patient with moderate anemia, 
this patient had a severe red cell morphology, significant reticulocytosis, increased HbF and 
iron over load.  A frame shift in the β-globin gene was found affecting the exon 2 at the region 
of amino acid codon 100.  There were an insertion of eight nucleotides in the β-globin gene 
that results in a shift of the normal protein reading frame and an abnormal amino acid 
sequence before codon 99.  The final product results in extended polypeptide chain of 159 
amino acid long.  The excess unstable β-chain and unpaired to α-chain leads to extensive cell 
damage (erythroblast destruction and ineffective erythropoiesis) (Williamson, Brown, 
Langdown, & Baglin, 1997). 
1.4.7   Other modifiers  
The phenotype of thalassemia always results from the allelic heterogeneity of beta globin gene 
and the effect of alpha and gamma globin gene mutations. Also the phenotype could be 
modified by other genetic factors mapping outside the globin gene cluster and not influenced 
with HbF.  These factors almost affect bilirubin, iron, and bone metabolism.  The rapid 
turnover of red cells in thalassemia patients results in jaundice and the probability to form 
gallstones.  Bilirubin and gallstones are related to polymorphic motifs at the promoter of the 
gene in hepatic glucuronidation of bilirubin.  In normal conditions the promoter has six TA 
repeats in the TATA box (TA)6, in thalassemia patients that develop hyperbilirubinemia, 
jaundice and gallstones have the more common and less efficient TA7 motif (Cao & 
Galanello, 2010). 
A common mutation of the HFE gene (C282Y) that cause the common type of Hereditary 
Hematochromatosis (HH) may be involved in determining the variability of iron overload in 
TI patients (Cao & Galanello, 2010). 
A polymorphism at the genetic loci involving bone metabolism mainly vitamin D receptor and 
the COLIAI gene, is associated with the development of marked osteoporosis that depends on 
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many factors including hypogonadism and the extent of iron chelation (Cao & Galanello, 
2010). 
1.5 . Clinical management of βTI 
Treatment of βTI is based on the symptoms and folic acid supplement and splenectomy (Cao 
& Galanello, 2010). Guidelines for the management of βTI have been published by the 
Thalassemia International Federation (M. Karimi et al., 2014). 
 
1.5.1. Transfusion therapy  
Transfusion is not a routine treatment of βTI patients. Occasional transfusion is recommended 
in pregnancy, surgery, and infection.  The initiation of transfusion therapy is based on the 
severity of signs and symptoms of anemia including failure of growth and development, 
enlargement of spleen and poor performance in school.  Alloimmunization is observed in βTI 
patients, although the risk is decreased when transfusion is initiated before 12 months of age.  
Testing for Rh antigens (D, C, E, c, e) and K1 (partial K) is recommended before transfusion 
therapy. Some physicians administrate steroids therapy for 3-5 days.  The increased intestinal 
iron absorption leads slowly to iron overload. In addition, transfusion therapy increases the 
risk of iron overload (A. T. M. Taher, K. M. Cappellini, M. D. Weatherall, D. J., 2011; 
Vichinsky, 2016). 
 
1.5.2. Iron chelation therapy  
Iron overload is the most common complication in βTI patients.  Iron accumulates and 
damages the tissues and cells. Excess iron causes a peroxidative injury to the phospholipids of 
mitochondria and lysosomes that produce free radicals (the most pathogenic factor). Hepcidin 
that regulates excess iron is low in thalassemia patients and result in excessive gastrointestinal 
absorption of iron even in the presence of iron overload. Ferritin can be used to measure iron 
overload, but recently the most reliable measurement and considered the gold standard for 
evaluation the iron overload  is the liver biopsy by  Magnetic Resonance Imaging (MRI) 
technique and particular  R2 and R 2* parameters that measure the correlation between liver 
iron and body iron.  Iron chelating is necessary to reduce the risk of hemosiderosis.  Recently; 
there are three chelating drugs available: Desferal that is administrated subcutaneously at a 
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median dose of 40 mg/kg over 8-12 hours.  Ferriprox (L1) that is an oral drug administrated in 
a dose of 75-100 mg/kg/day in three sub-doses given one hour before meal.  Exjade is an oral 
drug that has been approved by the Food and Drug Administration (FDA) and by the 
European Agency for the Evaluation of Medical Products (EMEA).  The dosage is 10-30 
mg/kg in one morning dose.  The oral chelating drugs are more efficient in chelating the 
excess iron pools of cardiomyocytes; attenuate reactive oxygen labile formation and binding 
labile iron (Borgna-Pignatti, 2007; Haddad, Tyan, Radwan, Mallat, & Taher, 2014). 
 
1.5.3 Bone marrow transplantation (stem cell transplantation) 
Bone marrow transplantation (BMT) means that the marrow of affected patient is replaced 
with marrow of unaffected patient (healthy patient).  Stem cell transplant is rare in βTI 
patients and is probably considered for severely transfusion dependent patients.   Successful 
BMT results in cure, but if it fails it may leads to other complications including graft versus 
host disease (GVHD) growth impairment, and neurologic complications and may lead to 
death.   The decision to make BMT depends on the quality of life, the expected survival time, 
availability of matched donor and this is relevant for βTI patients  especially who are mildly 
affected (Borgna-Pignatti, 2007; A. Taher et al., 2006). 
 
1.5.4. Modulation of fetal hemoglobin  
Enhancing γ-globin chain synthesis reduces the imbalance between α- and β-globin chains and 
potentially leads to improved RBC survival and alleviates anemia.  There are several 
pharmacological agents that increase γ-globin chain production by increasing Hb F.  Therefore 
such agents or drugs may become a potential therapy for patients with βTI.  
Hydroxycarbamide known as hydroxyurea HU is an S-phase-specific and non-DNA 
hypomethylating chemotherapeutic agent that induces HbF synthesis.  In a series study in Iran, 
the effects of HU in βTI patients were studied and found an increase in hemoglobin level in 
non transfused βTI patients, and the transfusion-dependent βTI patient became transfusion-
independent (Borgna-Pignatti, 2007). 
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Butyric acid and its derivatives are also postulated to augment HbF via their action at the 
sequences near the transcriptional starting sites of the γ-globin gene promoter.  In βTI patients 
the response was limited and not predictable (Carolyn Hoppe, 1999). 
 
1.5.5. Splenectomy 
The size of spleen increases with time in non-transfused βTI patients and could aggravate the 
anemia and sometimes causes neutropenia and thrombocytopenia.  Splenectomy allows the 
discontinuation of transfusion in the majority of the patients.  If gallstones are present, 
Cholecystectomy should be performed at the time of splenectomy to avoid two surgical 
interventions.  Complications following splenectomy include increased risk of infections and 
thrombophilia. Splenectomy should be avoided in children less than five years old because 
they have a high risk of fulminate post-splenectomy and sepsis (Borgna-Pignatti, 2007; 
Haddad et al., 2014; Hashemieh, 2016). 
 
1.5.6. Anticoagulant therapy 
The role of anticoagulant therapy is for the prevention of vascular diseases in βTI patients.  
Aspirin should be administrated to splenectomized patients with platelets >500*10
9
/L and 
Coumadin to patients who have experienced thromboembolic events (Musallam et al., 2011). 
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1.6. Recommendations for the management of thalassemia intermedia 
Despite the availability of several treatment options, there are no clear guidelines for 
managing βTI.  Management of βTI depends on two categories: first manage the 
complication, second what is recommended to prevent development of these complications. 
The recommendations are: 
 A guarded approach for the need of splenectomy and delay the initiation of transfusion 
until it is necessary. 
 Early initiation of transfusion and iron chelating if there is growth abnormality, poor 
performance and facial deformities. 
 Regular follow up with endocardiodoppler for cardiac complications. 
 Regular follow up of liver iron concentration with MRI. 
 Avoid smoking; prolong immobilization and use of oral contraceptives (A. Taher et 
al., 2006; A. T. M. Taher, K. M. Karimi, M. El-Beshlawy, A. Belhoul, K. Daar, S. et 
al, 2010). 
 
1.7. Prevalence and Geographic Distribution 
βTI is a clinical condition that is less severe than βTM and more severe than βTT. The 
prediction of phenotype from genotype in βTI is difficult due to genetic and environmental 
modifying factors.  A cross sectional study was conducted in China (2010), where the authors 
analyzed the genotype of 117 βTI patients that were diagnosed after the second year of age 
and their hemoglobin levels were (6-10 g/dl).  The common genetic defects in Chinese βTI 
patients fall into two types: type 1 β-thal homozygotes or compound heterozygotes for β-
globin gene  mutation and other β-globin defects were reported in 82.9% (97/117) of the  
study subjects in which β+-thalassemia mutations were the most common (49/97), HbE variant 
was the second (27/97) and deletional HPFH or δβ-thalassemia was the third (11/97); and type 
II β-thalassemia heterozygotes for β-globin gene mutations reported in 17.1% of patients. In 
βTI patients heterozygotes for β-globin gene mutations, only 5 of 20 patients co-inherited 
αααanti-3.7/ triplication, 14 patients had normal α-globin genes and 1 patient had a dominant 
frame shift β-thalassemia mutation at codon 53 (Chen et al., 2010). 
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βTI show a considerable heterogeneity in India. Researchers analyzed 73 cases of βTI in order 
to study the prevalence and the effect of common molecular determinants in βTI.  The 73 βTI 
patients were grouped into: homozygous β-thalassemia (n=50) and heterozygous β-
thalassemia (n=23).  The authors reported that the milder form of βTI is attributed to co-
inheritance of α-globing deletions (15/50), homozygous Omni polymorphism (17/50), both 
factors (3/50) and milder β-allele (9/50) in homozygous β-thalassemia (total 50 cases). While 
the heterozygote’s of β-thalassemia and αααanti-3.7/ triplication were the predominant factor 
(14/23 cases) (Inusha Panigrahi, 2006). 
Sollaino et al. (2009) have studied the association of α-globin gene quadraplication and 
heterozygous β-thalassemia in patients with βTI in Italy.  The authors analyzed the genotypes 
of 10 patients of βTI.  All patient had moderate to severe microcytic anemia (Hb 7-9.8 g/dl), 
increased HbA2 (>4.1%) and HbF (2.7-19.4%). All patients had shown one mutation, that is 
codon 39 C>T nonsense mutation in one β-globin gene and a complete normal sequence in the 
other β-globin gene. Multiplex Ligation-dependent Probe Amplification (MLPA) analysis of 
α-globin cluster revealed a complete duplication of α-globin gene in one family covering 170 
Kb from the telomere while other families showed larger duplications.  The duplication 
includes the regulatory elements MCS-R1, MCS-R2 (HS40), MCS-R3 and MCS-R4. This 
causes a more severe imbalance of the α/β globin chain ratio; the increase in imbalance 
enhances the ineffective erythropoiesis resulting in evident clinical symptoms.  Thus, the co-
inherited triple α-globin arrangement, converts the typical clinically asymptomatic β-
thalassmia carrier state into that of β-thalassemia intermedia phenotype (Maria  Caria 
Sollaino, 2009). 
Maragoudaki (1999) has studied the molecular, hematological and clinical manifestation of 
the -101 C>T substitution of the β-globin gene promoter in 25 βTI patients in Athens, Greece. 
All patients had moderate anemia with Hb levels between 8.7 and 10.5 g/dl.  Genotyping 
revealed that all patients were double heterozygotes for the -101 to C>T mutation and a 
second severe β-thal mutation in Trans with normal α-globin genotype in 24 patients and 
presenting with mild βTI phenotype. While one patient who shared the same β-globin 
genotype was transfusion depended because it has an additional α-globin gene mutation. All 
25 patients were normal for the Xmn I polymorphism in 
Gγ-globin gene (Maragoudaki, 1999). 
15 
 
Al-Allawi (2014) has studied the molecular basis of βTI in 74 patients from North Iraq. 
Patients showed Hb levels between 6.5 and11.6 g/dl and HbF ranging from 3.3 to 98.5% and 
Hb A2 ranges from 1.5 to 8.5%.   The most common mutation was IVS-I-6 (T>C) followed by 
IVS-II-1(G>A), codon 82/83 (-G) and codon 8 (-AA). Also the inheritance of β-thalassemia 
mutations and Xmn I polymorphism are the most important mechanism implicated in these 
βTI patients (Al-Allawi, Jalal, A. M. Omer, & S. Q. Markous, 2014). 
El-Shanshory (2014) has studied the different β-globin gene mutations in 158 βTM patients 
and 42 βTI patients from Egypt. The most common mutations were IVS-I-110 (G>A), IVS-I-6 
(T>C), IVS-I-1 (G>A), IVS-I-5(G>C), IVS-II-848(C>A), IVS-II-745 (C>G), IVS-II-I(G>A) 
(El-Shanshory, 2014). 
Ebrahim Miri-Moghaddam (2016) has studied the genotypes of β- and α-globin genes in 50 
cases with βTI including 5 patients with hemoglobin variants. The most common mutations 
were:  IVS-I-5 G>C, and IVS-II-1 G>A and the predominant genotypic combinations were 
βº/βº (68.9%). Coinheritance of α-thalassemia was observed in 33% of the patients with the -
α3.7 as the most common allele and one patient with the  –α4.2 allele and another patient with 
the –MED allele. However, the alleviating mechanism for the intermediate thalassemia 
phenotype was not explainable in more than half of the cases with the β°/β° genotype (Miri-
Moghaddam, 2016). 
Genetic analysis of β-Thalassemia Intermedia has been studied in Israel, Rund has analyzed 
95 βTI patients from 60 families including Arabs, Samaritan and Druze families. In 10 
families, the mild βTI phenotype was attributed to compound heterozygosity of -101 C>T or 
coexistence of triplicate α-globin genes with β-thalassemia trait. In 39 families, the sever 
phenotype of βTI was attributed to inheritance of sever β-thaassemia mutations. No beneficial 
effect for coinheritance of α-thalassemia in 11 families was studied. Elevated HbF levels 
ameliorated the disease in some patients with a severe genotype (Rund, 1997). 
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1.8. Problem statement 
β-Thalassemia intermedia  shows a considerably variable clinical picture ranging from mild to 
severe anemia requiring occasional blood transfusion. Genetically, βTI is a heterogeneous 
group that is attributed to mutations in β-globin gene alone or co-inheritance of β-globin gene 
mutations and other globin genes such as α- or γ-globin genes. The genetic determinants of β-
TI may be different in different regions and in particular in different ethnic groups and is 
affected by the different types of thalassemia alleles common in each area and ethnic group. 
Fortunately, from the more than 200 mutations causing β-thalassemia, only less than 20 
mutations are usually responsible for the β-thalassemia in each specific ethnic group. 
The proper diagnosis of βTI is challenging due to its genetic heterogeneity and thus requires 
careful considerations, so patients are correctly identified and given the appropriate treatment. 
A definitive diagnosis for βTI is possible through DNA analysis.  
 
1.9. Study justification  
Precise diagnosis and management are essential in β-thalasemia intermedia patients for 
prevention of later clinical complications and not to be confused with β-thalasemia major. β-
Thalassemia intermedia patients in West Bank region, were mostly diagnosed based on CBC, 
hemoglobin electrophoresis and clinical symptoms which do not completely resolve it from β-
Thalassemia major, and thus they most likely do not receive the appropriate clinical 
management. Misdiagnosis of βTI patients as βTM makes them vulnerable to inappropriate 
transfusion that loads their bodies with iron and increases their suffering from disease 
complications and compromises their life quality. 
 
1.10. Aim of the study  
The aim of this research is to study the molecular and hematological characteristics of β-
thalasemia intermedia in the West Bank, in order to provide a proper diagnosis and 
management of patients. 
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1.11. Objectives 
Palestine, like other countries in the region, has around 800 BTM patients and of whom more 
than 400 patients in the West Bank region. While the exact number of BTI patients is not 
exactly known. So far, no study has been conducted to determine the genetic mutations 
contributing to βTI.  Therefore, the objectives of the present study were; 
 
To determine the spectrum of genetic mutations that causes β-thalassemia intermedia in the 
West Bank region, Palestine. 
To investigate the hematological characteristics (Hb, Hb A2 and HbF levels) in βTI patient`s, 
and the level of clinical management of β-thalassemia intermedia in the West Bank region, 
Palestine.  
Provide background data that should improve the understanding of the genetic modifiers that 
contribute the phenotype of BTI in West bank region and to make an efficient use of health 
care resources. 
  
 
1.12. Hypothesis 
H0: β-thalassemia intermedia patients have a variant genetic mutation in the West Bank 
region, Palestine.  
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Chapter two  
________________________________________________________________ 
Materials and Methods  
2.1. Materials  
 
All reagents, chemicals and instruments used in this study are shown in table (2.1). 
Table 2.1: List of instruments and materials used in this study 
Item  Manufacturer/country  
Syringes Medi-Plus.  China   
Needles Medi-Plus. China   
EDTA tubes Sigma  
DNA extraction kits from whole 
blood  
Genomic DNA Mini kit, Geneaid, Cat #: GB100 
Lyophilized PCR master mix AccuPower
® 
HotStart PCR PreMix, BIONEER, Korea 
Gel purification kit  AccuPower
® 
Gel Purification kit, BIONEER, Korea 
PCR primers Metabion, Germany  
1kb  DNA ladder  Gene Direx 
® 
50 bp DNA  ladder  Gene Direx
® 
Agarose Hy-labs, Israel 
Ethidium bromide Hy-labs, Israel 
Thermal cycler  Esco Healthcare Ltd. USA 
Gel documentation system  Bio-RAD GEL DOC 2000. USA 
Tris base  Sigma  
DNAase free nuclease water  Hy-labs 
DiMethyl SulfOxide  (DMSO) Sigma  
Xmn I enzyme,  New England Biolabs, UK 
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2.2 Methods 
2.2.1. Study population and Design 
This was a case series retrospective multi-center study.  Thalassemia patients are registered in 
eight major centers in the major hospitals administered by the Palestinian Ministry of Health 
(MOH). These thalassemia centers are located in eight major cities in the West Bank of 
Palestine namely: Al-Watani Hospital (Nablus), Thabet-Thabet Hospital (Toulkarem), 
Sulieman Khalil Hospital (Jenin), Qalqiliyah Hospital (Qalqilia), Palestine Medical Complex 
(Ramallah), Alia Hospital (Hebron), Biet Jala Hospital (Beit Jala) and Jericho Hospital 
(Jericho).  
Patients’ medical files were reviewed retrospectively in the first visit by the researcher. A 
special questioner was used to collect demographic and medical data including patient`s age, 
sex, age on first blood transfusion, diagnosis, history of splenectomy / splenomegaly, onset of 
disease, serum ferritin level and any other relevant health complications. 
Data were analyzed and patients that met the inclusion criteria (see below) for β-thalassemia 
intermedia were identified and considered eligible for inclusion in this study.  
2.2.2. Inclusion criteria for β-thalassemia intermedia  
1. Diagnosis of TI. 
2. Age at diagnosis or initiation of transfusion ≥2 years. 
3. Frequency of blood transfusion, once every 2-3 months or even larger intervals. 
4. Questionable TM diagnosis like a patient who is more than 30 years old or has high 
HbA2 levels. 
2.2.3. Questionnaire  
Patients who fulfilled the inclusion criteria listed in the previous section were contacted by 
telephone and briefed about the study objectives and asked for participation in the study. The 
questionnaire developed for this study included two parts, the first part was used to collect 
data from medical files and the second part was used to collect data from the patient directly 
via a short interview Appendix 4. The questionnaire aimed to collect demographic information 
20 
 
and medical history of the patients. Patients who accepted to participate in the study, were 
asked to attend to the nearest clinical care center. Patients were asked to provide information 
to complete the second part of the questionnaire as well as to provide a written consent. For 
patients younger than 18 years old, the guardian (either father or mother) were asked to 
provide the information needed to complete the questionnaire and to provide the written 
consent form.  
2.2.4. Specimen collection, transport and preservation  
Two samples of venous blood were collected in K3EDTA tubes; each tube contained one to 
three milliliters of blood. One blood sample was used for CBC analysis using an automated 
hematology analyzer and the rest of the sample was used for Hb electrophoresis. The second 
sample was kept closed and used for DNA analysis.. Thus, study samples were analyzed using 
one of three different hematology analyzers (Nihon Kohden, Celltac and Abcus 380) were 
used for CBC analysis based on availability of the machine in the Health care centers where 
samples were collected.  Samples were sent to the research laboratory at Al-Quds University 
within 8 hours in a refrigerated box. One sample (same one used for CBC) was used for Hb 
electrophoresis that was performed using HPLC method on the D-10 machine (Biorad). The 
second sample was sent to Al-Quds University using a refrigerated box and stored at 6 ± 2
°
C 
and used for preparation of genomic DNA. 
2.2.5. Preparation of genomic DNA  
Genomic DNA was prepared by two methods: first, whole blood was used using a commercial 
kit (Genomic DNA Mini kit, Geneaid, USA). Briefly, 300 µL of whole blood were transferred 
into 1.5 mL micro centrifuge tube, followed by addition of 900 µL RBC lysis buffer, mixed 
by inversion, incubated for 10 minutes at room temperature then centrifuged at 3000 xg for 5 
minutes. The supernatant was removed and the pellet was resuspended in 100 µL of RBC lysis 
buffer, mixed well, 200µL of GB buffer was added, mixed vigorously and incubated for at 
least 10 minutes at 60°C. Then 200µL of absolute ethanol was added, mixed for ten seconds 
and the mixture was transferred to a GD column followed by centrifugation at 13000 xg for 
five minutes. The 2 ml collection tube and the through filtrate were discarded. The column 
was then washed with 400 µL of W1 buffer and centrifuged at 13000 xg for 60 second. A 
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second wash was performed using 600 µL of washing buffer followed by centrifugation at 
13000 xg for 60 second. Then, the GD column was dried by centrifugation at 13000 xg for 3 
minutes. After that, the GD column was transferred to a clean 1.5 mL microcentifuge tube, 
100 µL of preheated elution buffer was added, let stand at least three minutes then centrifuged 
at 13000 xg for 60 seconds to elute DNA. Purified DNA was stored at -20°C. 
Second: genomic DNA was prepared from Buffy coat to increase the yield of genomic DNA 
using a commercial kit (Genomic DNA Mini kit, Geneaid, USA). Briefly, whole blood was 
centrifuged at 3500 xg for 5 minutes. 200-300 µL of the buffy coat were transferred to 1.5 mL 
micro centrifuge tubes and mixed with 900 µL of RBC Lysis solution. Then the procedure 
was continued as described above for the whole blood.  
2.2.6 Assessment of DNA quality and quantity 
The quality and quantity of the DNA samples were assessed by loading them on 1% agarose 
gel parallel to 1 kB DNA ladder. Electrophoresis was performed at 100 Volts and gels were 
visualized using a UV transilluminator.  DNA samples were stained using ethidium bromide.  
 
Amplification of β-globin gene 2.2.7.1 
The 5’ part of β-globin gene was amplified using primer pair: Bglob-F1 and Bglob-R1 
yielding a 916-bp amplicon table (2.2). The 3’ end of the β-globin gene was amplified using 
primer pair: Bglob-F2 and Bglob-2 yielding a 667-bp amplicon. The latter two pairs of 
primers were described earlier(Clark & Thein, 2004). Gene amplification was done using 
Polymerase Chain Reaction (PCR) technique and the lyophilized Hot-start PCR master mix 
(AccuPower
® 
HotStart PCR PreMix, BIONEER, Korea).  This lyophilized master mix 
contained hot start Taq DNA polymerase, Buffer, MgSO4, dNTPs and the loading buffer.  
Primers, DNA samples and nuclease free water were added to the master mix as shown in 
Table (2.3) Thermal cycling was performed using a thermal cycler from Esco Healthcare Ltd 
(USA) as shown in table (2.4). 
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Table 2.2: Sequence and location of PCR primers used for analysis of  α- and β-globin genes 
as well as Xmn I polymorphism of 
Gγ-globin gene. 
Primer Sequence (5´3´) GenBank  
Accession no. 
Coordinates Gene 
 
Bglob-F1 CGA TCT TCA ATA TGC TTA 
CCA A 
U01317.1 61830  61851 Β 
Bglob-R1  CAT TCG TCT GTT TCC CAT 
TCT A  
U01317.1 62745 – 
62724 
Β 
Bglob-F2 CAA TGT ATC ATG CCT CTT 
TGC A 
U01317.1 63214 – 
63245 
Β 
Bglob-R2 TGC AGC CTC ACC TTC TTT 
CAT  
U01317.1 63870  63890 Β 
P51 CTGCACAGCTCCTAAGCCAC J00153 7254-7273 
11072-11090 
α2 
α1 
P52 CCTCCATTGTTGGCACATTCC J00153 7531-7551 α2 
P54 CTCAAAGCACTCTAGGGTCC
A 
J00153 11497-1517 α1 
P55 GTCCACCCCTTCCTTCCTCA J00153 5687-5706       
9247-9266 
Y2
1 
Y1
1 
P59 CTCTAGGTCACCCTGTCATCA J00184 26-46 Ψδ1 
P60 CTCTGTCGTGTAGACGCCGA M33022 423-442 θ2 
P71 TACCCATGTGGTGCCTCCAT
G 
J00153 3068-3088 Ψα1 
P72 TGTCTGCCACCCTCTTCTGAC J00153 8894-8915 NH-II
2 
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IVSID52 
W 
GGAGGCCCTGGAGACGTGAG Z84721 33847-33877 α2 
A2D5M GTATGGTGCGGAGGCCCTGG
AGACGC 
Z84721 33856-33875 α2 
A2R904 GTCTGAGACAGGTAAACACC
TCCAT 
Z84721 34642-34618 α2 
α-CF GGAGGGTGGAGACGTCCTG Z84721 33538-33556 
37344-37360 
α2 
α1 
X4GG158F AAC TGT TGC TTT ATA GGA 
TTT 
U01317.1 33862-33882 
 
Gγ 
XGG-158R TTT TAT TCT TCA TCC CTA 
GC 
U01317.1 34453-34434 
Gγ 
1Y1 and Y2 refer to homologous regions Y1 and Y2 overlapping α2 and α2-globin genes. 
2
NH-II: non-homologous region 2. 
 
Table 2.3: Amplification of β-globin gene 
Volume (µL) Reaction components 
0 Lyophilized master mix 
3 DNA sample (~30 ng/µL) 
0.5 Forward primer (10 µM) 
0.5 Reverse primer (10 µM) 
16 DEPC-Water  
20 Total volume  
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 Table 2.4: Amplification of β-globin gene using Thermal cycle program 
Temperature  Duration  Step Cycles 
94°C 5 min Initial denaturation  1X 
94°C 45 sec  
Denaturation  
35X 
55°C 45 sec Annealing  
72°C  80 sec Extension  
72°C 5 min Final extension  1X 
 
The PCR products were analyzed by running them on 1% agarose gel.  
2.2.7.2 Gel purification  
The gel was purified by cutting the target DNA fragment from the agarose gel and the DNA 
fragment was purified using the AccuPower Gel Purification kit (Bioneer, Korea) per the 
manufacturer’s instructions. Briefly, the gel slice was weighed in a clean 1.5 mL micro-
centrifuge tube.  Three volumes of the gel binding buffer were added to gel slice, incubated at 
60°C for 10 minutes and the mixture was mixed every 3 minutes.  One volume of absolute 
isopropanol was added to the mixture, mixed gently, the mixture was transferred to the DNA 
binding column tube and centrifuged for 1 minute at 13,000 xg The flow through was poured 
off and the DNA binding column was washed with 500 µL of buffer 2, centrifuged for 1 
minute at 13,000 xg, the flow was poured off and this step was repeated twice.  The DNA 
binding column was dried by centrifugation at 13,000 xg for 3 minutes to remove the residual 
propanol. The DNA binding filter was transferred to a new 1.5 mL micro centrifuge tube, 45 
µL of elution buffer were added to the center of the binding column, incubated at least 1 
minute at room temperature, and then the DNA fragment was eluted by centrifugation at 
13,000 xg for 2 minutes.  Purified DNA fragments were used for DNA sequencing. 
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The amplification products were analyzed by running the product on 1% agarose gel.  
 
2.2.7.3. DNA sequencing 
The purified DNA fragments or PCR products were sequenced using the Forward and reverse 
primers. For this purpose the PCR products along with either Forward or reverse primers were 
sent for DNA sequencing to Hy-labs laboratories in Jerusalem.  The DNA sequence results 
were analyzed visually and then using the BLAST bioinformatics tool.  
 
2.2.8.1 Analysis of α-globin gene deletion mutations 
The primers P51 to P72 (Table 2.2) were used for gap PCR analysis of deletion mutations of 
the α-globin genes (Oron-Karni, Filon, Oppenheim, & Rund, 1998). The primers P52 to P72 
were used in four different reaction mixtures (reactions A to D) for detection of the four 
common α-globin gene deletion mutations: -α3.7, –α4.2, --MED/ and αααanti3.7. Reaction A is a 
multiplex reaction which detects the
 –
MED/ mutation and contains the following primers: P51 
(60 ng), P52 (40 ng), P54 (60 ng), P59 (40 ng), and P60 (40 ng). Reaction B detects the - α3.7/ 
mutation and contains the following primers: P55 (60 ng) and P54 (60 ng). Reaction C detects 
the -α4.2/ mutations and contains the following primers: P71 (40 ng), P72 (60 ng), and P52 (20 
ng). Reaction D detects the αααanti3.7 triplication and contains the following primers: P55 (59 
ng), P52 (63.08 ng). All PCR reactions (reactions A to D) were performed with a Hot Start 
ready PCR mix (Bioneer) using ~100 ng of genomic DNA and 5 % DMSO.  Each 20 μL 
reaction contained the manufacturer’s buffer (1X), 1.5 mM MgCl2, 0.25 mM of each dNTP 
and Hot-Start Taq DNA Polymerase. Amplification was performed with an initial heat 
activation step of 5 minutes at 94°C followed by 35 cycles, each consisting of 94°C 1 minute, 
58°C for 1 minute, and 72°C for 2.5 minutes, and a final extension step of 72°C for 10 
minutes. The PCR products of reactions A to D were analyzed on 2% agarose gel and 
interpreted as described in Table (2.5). 
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Table 2.5: The α-globin gene genotypes detected using the multiplex gap-PCRs and the size 
of the corresponding amplicons in bp.  
PCR reaction 
 ---MED 
A 
-α 3.7 
B 
-α4.2 
C 
αααanti3.7 
D 
Primers P59-
P60 
P51-
P52 
P51-
P54 
P55-P54 P71-P72 P71-P52 P55-P52 
Alleles | 
Aα - 298 446 2271  233 1865 
-MED 561 - - -  - - 
-α4.2 -  446 2271 1596 - - 
-α3.7 -  446 2013  233 - 
Αααanti3.7       1865-2123 
 
For detection of the IVS2-5nt del mutation, ARMS PCR using the following primers 
IVSID52W, A2D5M and A2R904 was used as described by (Lacerna et al, 2007). The mutant 
forward primer A2D5M was slightly modified and the forward wild type primer IVSID52W 
was redesigned to increase the specificity of the RCR. The PCR reaction was performed with 
a Hot-start ready PCR mix (Bioneer) using ~100 ng of genomic DNA and 5 % DMSO.  Each 
20-μL reaction contained the manufacturer’s buffer (1X), 1.5 mM MgCl2, 0.25 mM of each 
dNTP, 0.25 µM of each forward and reverse primers and Hot-start Taq DNA Polymerase. The 
mutant sequence was amplified using the forward primer A2D5M and the common reverse 
primer A2R904. The Wild type sequence was amplified using the forward primer IVSID52W 
and the common reverse primer A2R904. Amplification was performed with an initial heat 
activation step of 5 minutes at 94°C followed by 30 cycles, each consisting of denaturation at 
94°C for 50 seconds, annealing at 60°C for wild type reaction or 62°C for the mutant reaction 
for 50 seconds, and extension at 72°C for 1 minute and a final extension step of 72°C for 5 
minutes. However, this ARMS PCR generated non-specific fragments that made accurate 
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discrimination of mutant and wild type alleles difficult and thus we decided to detect the 
IVS2-5nt del by DNA sequencing of the α2-globin gene. 
For DNA sequencing, the α2-globin gene was amplified using PCR primers, forward primer 
P52(Oron-Karni et al., 1998) and reverse primer α-CF (Clark & Thein, 2004) ). The α2-globin 
gene was amplified using the primer pair: α-CF and α2-R2, which yields an amplicon of 1084 
bp long. PCR amplification was performed using Hot-start ready PCR mix (Bioneer) using 
~100 ng of genomic DNA and 7.5 % DMSO. Each 20-µL reaction contained the 
manufacturer’s buffer (1X), Hot-Start Taq DNA polymerase, 1.5 mM MgCl2, 0.25 mM of 
each dNTP and 0.25 µM of each primer. Amplifications were performed with an initial heat 
activation step of 5 minutes at 94°C followed by 35 cycles, each consisting of  94°C for 1 
minute, 55°C for 1 minute and 72°C for 1.5 minute, followed by a final  extension step of 
72°C for 5 minute. The PCR product was analyzed on 1% agarose gel and purified from the 
gel as described in section (2.2.8.2).  DNA sequencing was performed as described as in 
section (2.2.8.3) 
 
2.2.9. Detection of XmnI polymorphism in Gγ-globin gene 
The Xmn I SNP (-158 C>T) at the 5’end of Gγ-globin gene was detected using RFLP-PCR. 
For this purpose the 5’ end of the Gγ-globin gene flanking the Xmn I SNP (-158 C>T) was 
amplified using the primers X4GG158F (Nadir Ali a, 2015) and XGG-158R (Rujito et al., 
2016)  
PCR amplification was performed using Hot-start ready PCR mix (Bioneer) using ~100 ng of 
genomic DNA. Each 20-µL reaction contained the manufacturer’s buffer (1X), Hot-Start Taq 
DNA polymerase, 1.5 mM MgCl2, 0.25 mM of each dNTP and 0.25 µM of each primer. 
Amplifications were performed with an initial heat activation step of 5 minutes at 94°C 
followed by 35 cycles, each consisting of  94°C for 1 minute, 55°C for 1 minute and 72°C for 
1 minute, followed by a final  extension step of 72°C for 5 minute. 
Ten µL of the PCR product (592-bp long) was digested with 5 Units of Xmn I enzyme for 2 
hours at 37°C. The Xmn I reaction was analyzed using 3% agarose gel. Xmn I digestion 
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generates 3 possible genotypes: 147, 445 bp (+, C allele); 592 (-, T allele) and 147, 445, 592 
bp (+/-, CT alleles). 
For confirmation of the RFLP PCR, 2 samples were analyzed by DNA sequencing of the PCR 
product. 
2.2.10. Ethical consideration 
The study protocol was approved by the Research ethics committee at Al-Quds University. A 
copy of the ethical approval is shown in Appendix 2. Also permission from the Ministry of 
Health was obtained to review the medical files of patients at Thalassemia care centers. A 
copy of the MOH approval is shown in Appendix 3. 
An informed consent was obtained from individual study participants or their guardians in 
case of minors. 
 
2.2.11. Statistical analysis 
Descriptive statistics including mean and standard deviation were calculated using SPSS 
version 22. 
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Chapter three 
Results 
3.1 Study samples 
This study aimed to determine the spectrum of genetic mutations associated with β-
thalassemia intermedia as well as to investigate the hematological characteristics and the level 
of clinical management of β-thalassemia intermedia in the West Bank region, Palestine. In 
order to determine the patients diagnosed with βTI, the researchers visited all eight 
Thalassemia Health Care centers in the West Bank and collected data about potential 72 cases 
of BTI that met the inclusion criteria of this study. All patients were contacted and asked to 
participate, but only 55 potential βTI patients accepted to participate in this study. Samples 
were collected in the period September 2016 to April 2017. From the 55 cases, 3 cases were 
found to have Sickle β-thalassemia and 1 case with Sickle Cell C disease and thus were 
excluded, leaving 51 unrelated cases of βTI for further investigation and analysis.  
 
The geographic distribution of βTI cases in the West Bank is shown in Figure (3.1). βTI cases 
were collected from 6 governorates, while none of the thalassemia patients at Jericho Hospital 
and Beit Jala Hospital fulfilled the inclusion criteria. The highest number of cases has been 
collected from Hebron and Nablus, respectively.  
 
Figure (3.1): Distribution of βTI cases based on residence place. 
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3.2 Clinical findings 
Fifty-one of βTI patients were enrolled in this study. The general characteristics of the 51 βTI 
patients are shown in Table 3.1. This study included 27 males and 24 females. The patients’ 
age ranged from 4 years to 71 years with a mean 18.9 years old. The low age mean of patients, 
shows that this is a young population where 26 patients (50.9%) are below 18 years old and 25 
patients (49%) are above 18 years old.  The age at diagnosis varied between one month and 25 
years with mean 2.9. Among the 51 βTI patients, 9 patients (17.6%) were never transfused, 
also 9 patients (17.6%) received occasional transfusions (once or twice a year), while the 
remaining 33 patients (64.7%) were receiving regular transfusion (three to four times per year) 
(Table 3.1).  
 
Analysis of the general health status of βTI patients revealed that 19 patients (37.2%) were 
splenectomized, while 9 patients (17.6%) suffer from splenomegaly. From the βTI patients 
who were never transfused (n=9), five patients were splenectomized; three patients were 
suffering from splenomegaly while one patient did not show symptoms of splenomegaly at 
time of enrollment in this study.   
From the 51 βTI patients, 31 patients have received Iron chelation therapy for at least one year 
at the time of enrollment. Iron chelating drugs that were used by the βTI patients included 
deferoxamine (Deferral) in eight patients, deferasirox (Exjade) in nineteen patients and, four 
patients used a combination of the latter two drugs.  Twenty βTI patients did not use iron 
chelation therapy. 
Most βTI patients were the result of consanguineous marriages, as the parents of all patients 
were relatives except three. None of the patients had ever leg ulcers, diabetes, hypertension 
(chronic disease) or documented venous thromboses. 
The level of Hb in βTI patients ranged between 6.4 and 13.9 g/dL with a median of 8.3 g/dL at 
the time of enrollment. The serum ferritin levels were taken from the medical files and were 
available for 31 patients only. Ferritin levels ranged from 92 to 8600 ng/mL with a median of 
1800 ng/mL.   
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Table 3.1: General characteristic of the 51 Palestinian β-thalassemia 
intermedia patients 
Parameter  Value 
Males, n (%) 27 (52.9%) 
Females, n (%) 24 (47.1%) 
Age, years 
 
Mean: 18.9 
95% CI: 15.9 – 21.8 
Age at diagnosis, years 
 
Mean: 2.9 
95% CI: 2.0 – 3.7 
Hb, g/dL 
 
Median:8.3 
Range: 6.4-13.9 
 
Serum Ferritin*, ng/ml 
 
Median: 1800 
Range: 92-8600 
 
Splenectomy , n (%) 19 (37.3%) 
Splenomegaly , n (%) 9 (17.6%) 
Transfusion frequency, n (%) 
 Never 
 Occasionally (1-2 times / year) 
 Regular (3-4 times per year) 
  
9 (17.6%) 
9 (17.6%) 
33 (64.7%) 
No. of patients on iron chelation 
therapy, n (%) 31(60.8%) 
*Ferritin levels are reported for 31 patients only.  
 
3.2 Hematological findings 
The level of Hb in βTI patients ranged from 6.4 to 13.9 g/dL with a median of 8.3 (mean of 
8.4 g/dL; 95% CI: 8.0 – 8.9) at the time of enrollment (Table 3.1). The serum ferritin levels 
were available for 31 patients and ranged from 92 to 8600 ng/mL with a median of 1800 
ng/mL (Table 3.1). In addition two patients who were never transfused, had high serum 
ferritin (>2700 ng/mL) and one patient was diagnosed at three years of age with the genotype 
β°/β°, has never been transfused and has an elevated level of serum ferritin (490 
ng/mL).Twenty two patients who had regular and occasional transfusion had high serum 
Ferritin >1000 ng/mL.  
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Hemoglobin electrophoresis was performed for all study samples (Table 3.3). Since most 
patients have a regular or occasional blood transfusion, patients were asked to donate blood 
samples for the study just before taking the next transfusion, mostly around 3 months after the 
last blood transfusion. HbF ranged between 1.3 and 83% While HbA2 ranged between 2.3 and 
8.5 %. The level of HbF and HbA2 showed large variations reflecting the different genetic 
mutations responsible for the thalassemic phenotype.    
 
 
3.3 β-thalassemia mutations  
Identification of the β-Thalassemia intermedia mutations among Palestinians was performed 
by Sanger DNA sequencing (Figure 3.2). A total of seven different mutations of β-globin gene  
were detected and comprised null mutations (β0) as well as mild mutations (β+) allowing 
reduced synthesis of β-globin chain (Table 3.2).  These seven β-globin gene mutations 
generated 10 genotypes, that in turn were responsible for the phenotype of βTI in our study 
subjects (Table 3.3). The most common allele of β-globin gene encountered was IVS-I-6 
(T>C) with a frequency of 76.5% followed by IVS-I-110 (G>A) with a frequency of 7.8% 
IVS –II-I (G>A) with a frequency 6.9% and the remaining 4 alleles IVS-I-I, codon 37, IVS-II-
848 and -101, accounted each for a frequency  of 1-3% (Table 3.2).  The most frequent single 
genotype was IVS-I-6 (T>C)/IVS-I-6 (T>C) with a frequency 74.5%, followed by IVS-II-
I(G>A)/IVS-II-I (G>A) with a frequency 5.8% and IVS-I-110 (G>A)/IVS-I-110 (G>A) with a 
frequency 5.8%, and the remaining 7 genotypes each accounted for about 2% (Table 3.3). 
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Figure 3.2: Representative chromatograms of the seven β-globin gene mutations detected in 
this study. 
 
 
 
 
IVSI-6 T>C, Homozygote IVSI-1 G>A, Heterozygote IVSI-110 G>A, Homozygote 
IVSII -848C>A, Heterozygote Beta -101 C>T, Homozygote Cd37 G>A, Heterozygote 
IVSII -1 G>A, Homozygote`  
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Table (3.2): β-Globin gene mutations detected in Palestinian β-thalassemia intermedia 
patients. Allele frequencies were calculated based on 102 chromosomes from 51 patients. 
 
Mutation  Nt. 
Substitution 
Type of 
mutation 
HGVS 
nomenclature 
Allele 
frequency (%)* 
IVS-I-6 T>C β+ HBB:c.92+6T>C 76.5 
IVS-I-I G>A β0 HBB:c.92+1G>A 2.0 
IVS-I-110 G>A β+ HBB:c.93-21G>A 7.8 
Codon 37 TGG>TGA β0 HBB:c.114G>A 3.0 
IVS-II-I G>A β0 HBB:c.315+1G>A 6.9 
IVS-II-848 C>A β+ HBB:c.316-3C>A 1.0 
Beta -101 C>T β++ HBB:c.-151C>T 2 
 
*The normal allele (βA) is present in one case from 51 patients and is not shown in the above 
table, making the sum of allele frequency 99.6 rather 100%.  
 
To enable analysis of phenotype-genotype correlations, all the βTI patients were grouped into 
four major genotypes (table 3.3) 
First: The mild genotype β⁺/β⁺ was further classified into four subgroups (Table 3.3). 
 Group I:  Homozygosity for IVS-I-6 C>T. This group included 38 patients showed a 
variable clinical picture with a mean Hb level of 8.4 g/dl.  From 38 patients, 24 patients had a 
regular blood transfusion, 7 patients had occasional transfusion, while the last seven had never 
been transfused. In this group, 15 patients were splenectomized while 6 patients suffer from 
splenomegaly. 
Group II:  Compound heterozygous for IVS-I-6 C>T / IVS-I-110 G>A with αIVSI(-5nt)α/ αα. 
This group included one patient with Hb vale of 8.7 g/dL. Hb electrophoresis was not 
determined because he had blood transfusion one month before sample collection. This patient 
had regular blood transfusion, was not splenectomized and showed no symptoms of 
splenomegaly at time of enrollment. 
Group III: Homozygosity for IVS-I-110 G>A.  This group included three patients. One of 
them had α3.7/ αα, the other two had normal α genotype. Two patients had regular blood 
transfusion while one had occasional transfusion. In addition, one patient was splenectomized; 
one suffered from splenomegaly and the third patient showed no symptoms of splenomegaly. 
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Group IV: Homozygosity of the silent mutation beta -101 C>T. This group included one 
patient and showed the highest Hb (13.9 g/dL) value among all study patients. The patient 
aged 13 years old and was never transfused. 
Among all 4 subgroups, group I showed the highest percentage of HbF (10.2 ±6.2%). 
 
The second genotype β⁺/β° was classified into three different heterozygote subgroups, each 
containing one patient. Hb values ranged from 6.5 to 7.1 g/dL. One patient (β-globin 
genotype: IVS-II-I G>A/ IVS-II -848 C>A) was heterozygote for α-thalassemia ( –α3.7/ αα) 
and 
Gγ-globin gene Xmn I  SNP and showed the highest HbF percentage.  All 3 patients with 
this β⁺\β° genotype had regular blood transfusion.  
The third genotype β⁺/βA was seen in one patient in association with α-globin gene 
triplication (αα/αααanti3.7), this patient had occasional blood transfusion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
 
Table (3.3): Hematological data, frequency of β- thalassemia mutations, α- thalassemia 
genotypes as well as Xmn I polymorphism of Gγ-globin gene among Palestinian β-thalassemia 
intermedia patients.  
β- thalassemia 
genotypes  
N (%) 
 
XmnI 
SNP 
α- 
thalassemia 
Hb  g/dL 
 
Hb A2 % 
 
Hb F % 
 
β⁺/β⁺             
IVS-I-6 / IVS-I-6  
38 
(74.5) -/- αα/ αα 8.4 ± 1.1 6.4 ± 1.4 10.2 ± 6.2 
IVS-I-6 / IVS-I-
110 
1 
(1.96) 
-/- 
 
 
αIVSI(-5nt)α/ 
αα 
 8.7 ND ND 
IVS-I-110 / IVS-I-
110  
 
3 
(5.88) 
 
-/- 
 
α3.7/ αα  
(1:0:0) 
9/11.7/9.5 
 
3.3/3.2/8.
5 
 
1.7/6.4/17 
 
Beta -101/ Beta -
101 
1 
(1.96) -/- αα/αα 13.9 4.6 7.4 
Subtotal  
43 
(84.3)           
β⁺/β°             
IVS-I-6 / Cd37   
1 
(1.96) -/- αα/ αα 6.9 3.3 6.6 
IVS-I-110 / Cd37 
1 
(1.96) -/- αα/ αα 6.5 2.5 30.9 
IVS-II-I / IVS-II -
848 
1 
(1.96) +/- –α3.7/ αα 7.1 3 49.1 
Subtotal  
3 
(5.88)           
β°/β°             
IVS-II-I / IVS-II-I 
3 
(5.88) +/+ αα/ αα 8.7 ± 0.86 2.1 ± 0.23 72.7 ± 7.3 
IVS-I-I / Cd37  
1 
(1.96) -/- 
αIVSI(-5nt)α/ 
αα 
 8.7 2.9 46.8 
Subtotal  
4 
(7.84)           
β⁺/βA             
IVS-I-I / βA 
1 
(1.96) -/- 
αα/ 
αααanti3.7 ND 3.8 6.3 
Total  
51 
(100)           
ND: Not determined. 
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The forth genotype is β°/β°. This group was comprised of four patients with Hb values 
ranging from 7.7 to 9.8 g/dL. Usually, β-thalassemia patients with β°/β° genotype and 
normal α- globin gene show the βTM phenotype Three patients were homozygout for  Gγ-
globin gene Xmn I SNP and one patient was heterozygote for α-thalassemia (αIVSI(-5nt)α/ 
αα).  Three patients had regular blood transfusion and one was never transfused. One 
patient was splenectomized and one showed symptoms of splenomegaly (Table 3.4). This 
group also showed the highest percentage of HbF among the four groups listed in Table 
3.3. 
 
 
Table (3.4): Hematologic data and genetic modifiers for the 4 βTI patients with β0/β0 
genotype. 
Patient  1 2 3 4 
Age / age at diagnosis 17/6 16/5 29/3 39/1 
Age at first transfusion, 
years 6 5 <1 1 
Hb, g/dL 7.7 8.6 9.8 8.7 
MCV, fL 66.5 91.8 76.4 99.0 
MCH, pg/cell 23.1 26.1 26.2 28.6 
HbF, % 68.0 67.0 83.0 46.8 
HbA2, % 2.3 1.8 2.3 2.9 
β-thalassemia genotype  
 
IVS-II-I/ 
IVS-II-I 
IVS-II-I/  
IVS-II-I 
IVS-II-I/ 
IVS-II-I 
IVS-I-I/  
Cd37 
XmnI SNP γG -158 C>T +/+ +/+ +/+ -/- 
α- thalassemia genotype 
  
αα/αα 
 
αα/αα 
 
αα/αα 
 
αIVSI(-5nt)α/ αα 
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3.4. α-thalassemia mutations  
The five common α- thalassemia deletion mutations were detected using gap-PCR (-α3.7/, -
α4.2/, --MED/ and αααanti 3.7) or DNA sequencing (α2-IVSI-5nt del). Four different multiplex 
gap-PCR reactions (reaction A to D) were performed for the detection of four deletion 
mutations affecting the α-globin genes: -α3.7/, -α4.2/, --MED/ and αααanti 3.7, respectively.  
These mutations represent the most prevalent deletion mutations affecting the α-globin 
genes in the Mediterranean region.  Representative agarose gels for reactions A to D are 
shown in Figures 3.3-3.6 
 
Figure 3.3 : Representative agarose gel for the –MED/ multiplex PCR reaction.   
Lanes 1-5: negative for –MED/αα mutation; Lane L: 50 bp DNA ladder. 
 
 
Figure 3.4: Representative agarose gel for the –α4.2 PCR reaction. Lanes 1-5: negative for 
–α4.2 mutation; Lane L50: 50 bp DNA ladder; Lane L1: 1kb DNA ladder. 
1              2              3             4              5               L 
446 bp 
293 bp 
293 bp 
L50            L1            1              2              3             4             
5    
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Figure 3.5: Representative agarose gel for the –α3.7 PCR reaction. Lanes 1-5: negative for 
–α3.7/ mutation, lane 6: –α3.7/αα genotype; L1: 1 kb DNA ladder; L50: 50 bp DNA ladder. 
 
 
 
Figure 3.6: Representative agarose gel for the αααanti 3.7 PCR reaction. Lanes 1-5: negative 
for αααanti 3.7 triplication; lane 6: αααanti 3.7 triplication; L1:  1 kb DNA ladder; L50: 50 bp 
DNA ladder. 
 
 
 
 
 
 
 
2271 bp 
L1            1           2           3            4             5           6           L50    
2013 bp 
3 bp 
2271 bp 
 L1        1        2          3          4        5        6        L50    
2013 bp 
40 
 
For detection of the αIVSI(-5nt) mutation, the 5’ region of the α2-globin gene including exons 
1 and 2 were amplified by PCR and analyzed by Sanger DNA sequencing. Two cases of 
βTI were found heterozygote for this mutation. A representative chromatogram showing 
this mutation is shown in Figure 3.7.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Identification of α2-IVSI-5nt del mutation by DNA sequencing. (A) Wild type 
allele.  (B) Mutant allele.  The double headed arrow indicates the 5 nucleotides deleted in 
this mutation.  
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From the 51 patients` samples analyzed, 5 samples (9.8%) were found to have α-
thalassemia mutations. Two patients were heterozygote for -α3.7/ mutation, two patients 
were heterozygous for α2-IVSI -5nt/ del mutation and one patient was heterozygote for the 
αααanti 3.7/ mutation.   The -α4.2/ and --MED/ mutations were not detected in this study. Table 
(3.5) summarizes the α-thalassemia genotypes detected in this study 
 
Table (3.5): α-thalassemia genotypes detected among 51 βTI patients. 
Mutation  No. Percent (%) 
-α3.7/ 2 4 
αααanti 3.7/ 1 2 
-α4.2/ 0 0 
--
MED
/ 0 0 
α2-IVSI -5nt del/ 2 4 
Total  5 10 
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3.5. Xmn I polymorphism of the Gγ-globin gene  
The Xmn I SNP ( -158 C>T, rs7482144) of Gγ-globin gene was detected by RFLP PCR.  
Out of 51 βTI patients, four patients (7.8%) were positive for  Gγ-globin gene Xmn I SNP. 
A representative agarose gels for this mutation is shown in Figure 3.8.  
 
Figure 3.8: Representative agarose gel of RFLP-PCR for the 
Gγ-globin gene Xmn I SNP. 
Lanes 2, 3,5: negative for Xmn I polymorphism (-/-); lanes 1, 4: heterozygous for Xmn I 
(+/-), lad: 50-pb DNA ladder. 
 
Figure 3.9: Representative agarose gel of RFLP-PCR for the 
Gγ-globin gene Xmn I SNP. 
Lane 2: negative for Xmn I polymorphism (-/-); lanes 1: homozygous for Xmn I (+/+), lad: 
50-pb DNA ladder. 
 
592 
bp 
445
147 
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For confirmation of the RFLP PCR, 2 samples were analyzed by DNA sequencing of the 
PCR product. A representative chromatogram showing this mutation is shown in Figure 
3.7.  
 
Figure 3.10: Identification of 
Gγ-globin gene Xmn I SNP by DNA sequencing.  
3.6 Genetic modifiers of HbF levels 
Several genetic modifiers for HbF levels in β-thalassemia have been reported. In this study 
the 
Gγ-globin gene Xmn I SNP and α-thalassemia mutation were examined (Table 3.6). 
The 3 βTI patients who were homozygote for the Xmn I SNP showed the highest average 
of HbF compared to HbF percentage of all samples or that heterozygote for α-thalassemia 
(Table 3.6). One sample was heterozygote for Xmn I SNP and α-thalassemia showed HbF 
percentage that is higher than the average of samples heterozygote for α-thalassemia, but 
lower than that of samples homozygote for Xmn I SNP.  However, the limited number of 
samples positive for either Xmn I SNP or α-thalassemia does not permit a reliable 
statistical comparison of means among these groups. 
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Table 3.6: Genetic modifiers of HbF level among βTI patients. HbF percentages of all βTI 
patients are compared with samples homozygous and heterozygote for Xmn I SNP, α-
thalassemia or a combination of both.  
 All samples  Xmn I SNP  
(+/+) 
α-thalassemia 
Heterozygotes 
Xmn I SNP 
& α-thalass 
N 51 3 5 1 
HbF % 
Median 
Range (min– max) 
 
10.4 
1.7 – 83.0 
 
67.5 
49.1 – 83.0 
 
26.6 
1.7 – 49.1 
 
49.1 
-- 
Hb g/dL 
Median 
Range (min-Max) 
 
8.3 
6.4 – 13.9 
 
8.6 
7.7 – 9.8 
 
8.7 
7.1 – 9.0 
 
7.1 
-- 
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Chapter   Four 
Discussion  
Thalassemia is one of the most common genetically autosomal recessive disorders in the 
world as well as in Palestine.  There are more than 200 genetic mutations responsible for 
the decreased production of β-globin chain (Georgiou et al., 2003).  β-Thalassemia 
intermedia (βTI) is a type of thalassemia that lies between the two extreme transfusion 
dependent βTM and transfusion independent βTT. Different genetic mutations are 
responsible for βTI phenotype, including the inheritance of severe, mild or silent β-
thalassemia alleles, coinheritance of α-thalassemia, and certain polymorphisms in γ-globin 
genes (Al-Allawi et al., 2014).  The aim of this research is to study the molecular and 
hematological characteristics of βTI in the West Bank region, in order to establish the 
common genetic basis for βTI prevailing among Palestinian βTI patients and to provide a 
better diagnosis and management of patients. 
 
A total of 51 βTI patients were investigated in this study. Most of the patients were from 
Hebron (39.2%), followed by Nablus (29.4%), Jenin (9.8%), Qalqilia (7.8%), Toulkarem 
(7.8%) and Ramallah (5.8%). The average age of βTI patients was 18.9 years and almost 
half of them (50.9%) were less than 18 years old (Table 3.1) which indicate that these 
patients are mostly a young population.  
 
Analysis of the health data of the study patients showed that 64.7% of the patients had 
regular blood transfusion and the average Hb was 8.4 g/dL. Hb level should not be an 
indicator for initiation of transfusion therapy, except in patients with considerably severe 
anemia (Hb level <5 g/dL)(A. Taher, Vichinsky, Musallam, Cappellini, & Viprakasit, 
2013) 
 
In addition, the median serum ferritin among the study patients was 1800 ng/mL (range 
92–8600 ng/mL) and only 31 patients received iron chelation therapy. The transfusion 
frequency is inappropriate and should be reviewed case by case to determine which case 
needs reduction of transfusion frequency. Since transfusion therapy should be restricted 
and used carefully to avoid complications associated with iron overload. In this regard, 
previous reports (Olivieri et al., 1994) showed that there is a significantly reduced risk for 
cardiac diseases and death in two-thirds of cases when ferritin levels were maintained 
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below 2500 ng/mL. In addition, other studies showed that a better prognosis for survival 
was associated with a low serum ferritin levels (Borgna-Pignatti, 2007; Rajaeefard et al., 
2015; Roudbari, Soltani-Rad, & Roudbari, 2008). Several factors contribute to 
accumulation of iron in body tissues or iron overload including ineffective erythropoiesis, 
anemia and hypoxia leading to a compensatory increase in erythropoietin and a decrease in 
serum hepcidin. This in turn will increase intestinal iron absorption and liver iron 
accumulation(M. D. Cappellini, Cohen, Porter, Taher, & Viprakasit, 2014). 
 
HbF values among our βTI patients ranged between 1.7 and 83% While HbA2 values 
ranged between 2.3 and 8.5 %.  The levels of HbF and HbA2 showed large variations 
reflecting the different genotypes responsible for the thalassemic phenotype among the 
study patients. 
 
A total of seven different mutations of HBB gene were detected and comprised null 
mutations (β0) as well as mild mutations (β+) allowing reduced synthesis of β-globin chain. 
The most common allele of HBB gene encountered was IVS-I-6 (T>C) with a frequency of 
76.5%, followed by, in decreasing order: IVS-1-110 (G>A), IVS –II-1 (G>A), Cd37 
(G>A), IVS-I-1 (G>A), beta -101 (C>T) and IVS-II-848 (C>A) (Table 3.2). These results 
are interesting because the IVS-I-6 (T>C) allele was detected in a high percentage among 
our βTI patients.  
 
In consistence with our results, this allele was found to be the most frequent allele among 
Israeli Arabs with βTI (or Palestinians in Israel; (57.7%)) (Rund, 1997), as well as among 
β-thalassemia patients from West Bank region (28.7%) (Darwish, El-Khatib, & Ayesh, 
2005) and Southern region of West Bank (48.5%) (El-Latif, Filon, Rund, Oppenheim, & 
Kanaan, 2002) as shown in Table 4.1. While, the IVS-I-6 (T>C) allele was the third 
frequent allele among Palestinian β-thalassemia patients from Gaza strip (Sirdah et al., 
2013).  The current study included only βTI patients whose genotypes are mostly 
contributed by mild HBB genotypes (β+). This in turn may partially explain the different 
frequencies of the IVS-I-6 (T>C) allele among our βTI patients compared to the other two 
studies from the West Bank (Darwish et al., 2005; El-Latif et al., 2002) that used a mixed 
sample mostly comprised of βTM patients. In addition, the IVS-I-6 (T>C) allele is a mild 
allele and is probably less frequent among βTM patients compared to βTI patients. In 
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addition, the different frequencies of HBB mutations among our βTI patients compared to 
β-thalassemia patients from Gaza strip (Sirdah et al., 2013) reflects different genetic 
background of the Palestinian tribes in both regions of Palestine.  
 
In contrast, analysis of the frequency of IVS-I-6 (T>C) allele among β-thalassemia 
patients in neighboring Arab countries showed that this allele was ranked as the second, 
third, fifth or sixth common allele, among other HBB alleles, in Iraqi Arabs (Al-Allawi, 
Puehringer, Raheem, & Oberkanins, 2015), Egyptians (Jiffri, Bogari, Zidan, Teama, & 
Elhawary, 2010), Lebanese (Makhoul et al., 2005), Jordanians (Sadiq, Eigel, & Horst, 
2001) and Syrians (Jarjour, Murad, Moasses, & Al-Achkar, 2014), respectively. 
 
Among our TI patients, 10 genotypes of HBB gene were detected.  Of these genotypes, the 
most frequent single genotype was IVS-I-6 (T>C)/IVS-I-6 (T>C) and was encountered in 
74.5% of βTI patients, followed by IVS-II-1(G>A)/IVS-II-1 (G>A) and IVS-I-110 
(G>A)/IVS-I-110 (G>A) that were each encountered in 5.9% of βTI patients Table (3.3). 
The remaining six genotypes were each detected in 2% of βTI patients. These results 
indicate that the major contributing factor for βTI among our study population is the 
inheritance of the mild HBB allele (β+) and namely IVS-I-6 (T>C) allele. 
 
The second common mutation identified in this study was the Mediterranean IVS-I-110 
G>A with allele frequency of 7.8%.  This allele was found to be the most frequent allele 
among β-thalassemia patients in Gaza strip (33.9%) (Sirdah et al., 2013). In addition, 
earlier reports from Palestine, found that the IVS-I-110 G>A allele  was the second 
frequent allele among β-thalassemia patients in West Bank (17.1 %) (Darwish et al., 
2005), and the third frequent allele among β-thalassemia patients from Southern region of 
West Bank (9.5 %) (El-Latif et al., 2002).  
 
In contrast, analysis of the frequency of IVS-I-110 G>A allele among β-thalassemia 
patients in neighboring Arab countries showed that this allele was ranked as the first 
common allele in Egyptians (Jiffri et al., 2010), Lebanese (Makhoul et al., 2005), 
Jordanians (Sadiq et al., 2001), Greece (Georgiou et al., 2003), and Syrians (Jarjour et al., 
2014), while it is the third frequent allele in Iraqi Arabs (Al-Allawi et al., 2015).  
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The third frequent mutation was IVS-II-1 G>A with an allele frequency of 6.9%, which is 
considered as a severe HBB allele (β°).  Earlier reports from Palestine, reported this IVS 
II-1 G>A allele as the eighth and fifth frequent allele among β-thalassemia patients from 
West Bank (2.9 %) (Darwish et al., 2005), and from Southern region of West Bank (4.4 
%) (El-Latif et al., 2002).  However, this allele was not detected in Gaza strip (Sirdah et 
al., 2013). It is the most common mutation in Iraqi Arabs 41.2% (Al-Allawi et al., 2015), 
and the second frequent allele in  Israeli Arabs  (Rund, 1997). 
 
The next two alleles (IVS-I-1 and Codon 37) were found in our study at a lower frequency 
compared to previous reports from Palestine (El-Latif et al., 2002) (Darwish et al., 2005; 
Sirdah et al., 2013).  A previous study from Gaza Strip reported the IVS-I-1 allele as the 
most frequent allele and even showed a milder severity compared to the IVS-I-110 (Ghoti, 
Fibach, Rachmilewitz, Jeadi, & Filon, 2017). 
 
The  allele (IVS-II-848 C>A) was reported earlier in West Bank (Darwish et al., 2005) and 
at very low frequency among Jordanians (Sadiq et al., 2001), Syrians (Jarjour et al., 2014) 
and Iraqi Arabs (Al-Allawi et al., 2014).  
 
The allele beta -101 C>T was found at a low frequency in our study (2%) and this is the 
first report of this allele in Palestine. This allele was reported at a lower frequency in Syria 
(Jarjour et al., 2014) and Lebanon (Makhoul et al., 2005). 
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Table (4.1): The allele frequencies of β-thalassemia mutations in the current study compared to earlier studies from Palestine, other neighboring 
and some Middle Eastern countries.  
Nationality/ country Palestinians Israeli 
Arabs 
Jordan Syria Lebanon Egypt Iraqi Arabs Greece 
Region WB WB WB/s Gaza 
Phenotype TI TM, TI
1 
Mixed
a2
 TM, TT TI Mixed 
a5 
TM, TT Mixed
a 
TM TI TM, TI 
No. of alleles 
analyzed 
102 279 136 274 53 240 331 520 188 204 1179 
Mutations            
IVSI-6 T>C 76.5 28.7 48.5 13.1 57.7 8.3 4.8 14.4 20.2 24 7.2 
IVSI-110 G>A 7.8 17.6 9.5 33.9 8.5 25 15.7 34.2 57.4 11.3 42.5 
IVSII-1 G>A 6.9 2.9 4.4 - 11.3 15 9.1 8.6 5.3 41.2 2 
Cd37 TGG>TGA 3.0 10.4 11.3 2.6 1.4 6.3 2.1 -  0.5 - 
IVSI-1 G>A 2.0 9.0 4.4 21.2 - 10 13.5 15 9.6 2 13.2 
Beta -101 C>T 2.0 - - - - - 0.6 - - 0.5 - 
IVSII-848 C>A 1.0 2.5 - - - 1.3 0.6 - - 1.5 - 
Cd106/107 (+G) - 6.8 - - - - - - - - - 
Cd39 C>T - 4.6 2.2 9.5 2.8 4.6 13.3 0.2 2.1 0.5 16.9 
Cd5 (-CT) - 2.5 8.1 0.4 - 3.8 4.5 5 - 0.5 1.12 
Not-genotyped - 8.2 3.7 - 5.6 1.6 7.8 0.2 - - - 
Wild  1.0 - -  4.2 - -   1.5 - 
Total No. of 
mutations  
7 17 10 15 7 19 31 20 7 22 10 
References  (Darwish 
et al., 
2005) 
(El-Latif 
et al., 
2002) 
(Sirdah 
et al., 
2013) 
(Rund, 
1997) 
(Sadiq 
et al., 
2001) 
(Jarjour 
et al., 
2014) 
(Makhoul 
et al., 
2005) 
(Jiffri et 
al., 
2010) 
(Al-Allawi 
et al., 2014) 
(Georgiou 
et al., 
2003) 
WB: West Bank region; WB/s: southern part of WB. TI: β-thalassemia intermedia; TM: β-thalassemia major; TT: β-thalassemia trait; aMixed: 
included TM, TI and TT and/or Sickle B-thalassemia but did not specify the allele frequency in each subgroup.  
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The coinheritance of α-thalassemia in association with homozygous or compound heterozygous 
β-thalassemia would reduce the excess alpha chains, and thus leads to a less severe phenotype. α-
Thalassemia mutations were seen in five patients only (9.8%); one of these five patients, whose 
HBB genotype was  βº/β⁺ and HBA2 genotype was –α3.7/αα was also heterozygous for the Gγ-
globin gene Xmn I SNP, two were β⁺/β⁺ (one with α2-IVSI-5nt and the other with-α3.7/αα); one 
βº/βº with α2-IVSI-5nt and the last one was β⁺/βA with  α-triplication (αα/αααanti3.7). 
Similar findings were reported from regional and neighboring Arab countries, where 7.8% (4/51) 
of Iraqi (Al-Allawi et al., 2014) and 9.8% (5/52) of Iranian βTI patients (Neishabury et al., 2008) 
showed coinheritance of α-thalassemia mutations. The βTI phenotype of another patient whose 
HBB genotype was β0/β0 which is supposed to be severe, is probably ameliorated by co-
inheritance of at least two genetic modifiers, namely the existence of an α-thalassemia mutation 
(αIVSI(-5nt)α/ αα)  and existence his high HbF level (46.8%). In the latter case, the high levels of 
HbF is probably  caused by genetic modifiers influencing HbF production (Lai et al., 2016) 
(Mejri et al., 2016). 
In the other two patients whose HBB genotype was β+/β+ and co-inherited an additional α-
thalassemia mutation, their Hb level is slightly above the average Hb of the study sample and 
thus the α-thalassemia mutation has probably slightly influenced  their phenotype.  Similar 
findings were reported in  two of four members of a Jordanian family whose HBB was β+/β+ and 
HBA genotype –α3.7/αα, they were reported as non-transfusion dependent (A Al Qaddoumi, 
2006). 
 
One patient was heterozygous for the HBB gene (β⁺/βA), but he co-inherited the α-triplication 
(αα/αααanti3.7), which explains his βTI phenotype. Since such alpha triplication increases the 
globin chain imbalance among β- thalassemia heterozygote and shifts the disease severity from 
βTT toward the βTI phenotype (Farashi et al., 2015; Thein, 2005; Traeger-Synodinos et al., 
1996).  A similar findings in Israel was reported  for a βTT patient, who showed severe anemia 
and splenomegaly, although his HBB genotype was β⁺/βA but his HBA genotype was αα/αααanti3.7 
(Steinberg-Shemer et al., 2017). 
 
Analysis of the Gγ-globin gene Xmn I SNP showed that three patients were homozygous and one 
patient was heterozygous for this SNP, three of them have the β0/β0 genotype and one has the 
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β0/β+ (in addition to –α3.7/ αα) and the effect of this SNP was clearly illustrated by the high levels 
of HbF in these patients. The role of Gγ-globin gene Xmn I SNP in increasing HbF levels and 
moderation of thalassemia phenotype is widely known and reported in many earlier studies (Ali 
et al., 2015) (Rujito et al., 2016) (Al-Allawi et al., 2014).  The Xmn I polymorphism is one of 
three major HbF quantitative trait loci (QTLs) responsible for HbF variation, and it leads to a 
less severe phenotype by increasing 𝛾-chain production, which helps to neutralize unbounded α-
chains (Borgna-Pignatti, 2007; Chan, Lau, Cheng, Chan, & Ng, 2016). 
 
Analysis of the 
Gγ-globin gene Xmn I polymorphism, showed that this SNP was found in 4/51 
patients (7.84%). Three homozygous patients showed the β°/β° genotype and one heterozygous 
patient (1.96%) showed the β°/β⁺ genotype, but it was not detected in any patient with the 
genotype β⁺/β⁺ or the β⁺/βA. The latter findings are consistent with earlier reports that the Xmn I 
SNP is the commonest ameliorating factor in cases with β° mutations and in particular with β° 
allele but not β⁺ (Al-Allawi et al., 2014; Arab et al., 2011).  However, in our study the 
percentage of βTI patients having the Xmn I SNP was low, in consistence with an earlier report 
from Barzil (9.7%)(Fonseca et al., 1998) but inconsistent to previous reports from Iraq 
(56.8%)(Al-Allawi et al., 2014) Iran (51.9%); (Neishabury et al., 2008) Pakistan (23%); (Ali et 
al., 2015) and China (26.5%) (Chen et al., 2010).  
It is interesting that the three patients with the β0/β0 (IVS II-1/ IVS II-I) and homozygous for 
Xmn I SNP not only have a high level of HbF but also have Hb levels (mean ± SD= 8.7 ± 0.86) 
above the average levels of the study patients. A recent study on a cohort of Palestinian β-
thalassemia patients from Gaza strip reported a milder phenotype for the homozygous IVS-I-I 
allele and association between this allele and the high expression level of HbF (Ghoti et al., 
2017). Ghoti el al 2017, found Xmn I SNP in only 7 out of 15 patient’s homozygotes for the IVS-
I-I allele, thus other genetic factors probably contribute to the high levels of HbF in association 
with null allele, which yet have to be determined. In addition, other studies have also reported an 
amelioration of the HBB  β0 allele by inheritance of either the Xmn I SNP, including reports from 
Egypt, that showed that patients with the IVS-II-I allele have relatively higher XmnI 
polymorphism frequency (50%) than IVS-I-6 and IVS-I-110 (Said & Abdel-Salam, 2015), and a 
report from Southern Iran showed that 87.5% of patients with the IVS-II-1 allele were 
homozygous for the Xmn I SNP (Mehran Karimi et al., 2002). 
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Further studies with a larger number of patients and analysis of major QTL, HBB haplotypes and 
detailed analysis of the promoters of γ-globin genes may help reveal the genetic modifiers 
contributing to the variations in HbF and milder phenotype associated with the IVS-II-I allele.  
 
In conclusion, this study is the first one to report the molecular characterization of βTI in 
Palestine. In βTI patients Hb level is adequate; the transfusion frequency is inappropriate and 
should be reviewed case by case to determine which case needs reduction of transfusion 
frequency. Since Transfusion therapy should be restricted and used carefully to avoid iron 
overload.  Genotyping of the HBB gene detected 7 different mutations and 10 genotypes. The 
IVS-I-6 allele was the major allele with a remarkably high allele frequency of 76.5%. The beta -
101 C>T mutation was diagnosed in one patient in homozygote state for the first time in 
Palestine. The inheritance of the mild HBB homozygote IVS-I-6 allele was the major 
contributing factor for the βTI phenotype among study subjects. The role of Xmn I SNP and α-
thalassemia mutations in ameliorating the thalassemia phenotype was observed in few patients 
for each factor. 
 
 
 
Recommendation 
 
Further studies with larger number of patients and analysis of more genetic factors inside and 
outside the globin genes could provide more data on the genotype-phenotype correlation of 
certain null HBB genotypes associated with milder phenotype. 
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Appendix 1 
Table1: Hemoglobin, Hb electrophoresis and genetic profiles for the study samples 
Number β Genotype Xmn 
I   
α-
Genotype  
Age 
(yr) 
Sex Age at 
diagnosis 
(Yr) 
Hgb(g/dl) Hb 
A2 
(%) 
Hb F 
(%) 
1 IVS-I-6 / IVS-I-6  x-/- αα/αα 11 M 5 8.3 7.7 5.3 
2 IVS-I-6 / IVS-I-6  x-/- αα/αα 11 F 8 7.6 5.8 13.8 
3 IVS-I-6 / IVS-I-6  x-/- αα/αα 7 M 5 7.7 5.3 10.4 
4 IVS-I-6 / IVS-I-6  x-/- αα/αα 34 F 2 8.2 8.2 5.3 
5 IVS-I-6 / IVS-I-6  x-/- αα/αα 36 F 4 7.7 7.7 11.3 
6 IVS-I-6 / IVS-I-6  x-/- αα/αα 13 M 0.08 7.8 4.8 8.3 
7 IVS-I-6 / IVS-I-6  x-/- αα/αα 35 M 4 8.7 6.2 24.2 
8 IVS-I-6 / IVS-I-6   x-/- αα/αα 4 F 0.66 9 6.4 29 
9 IVS-I-6 / IVS-I-6   x-/- αα/αα 60 M 25 7.1 4.7 1.3 
10 IVS-I-6 / IVS-I-6   x-/- αα/αα 54 F 16 7.5 8.6 6.6 
11 IVS-I-6 / IVS-I-6   x-/- αα/αα 13 F 0.58 9 4.5 5.3 
12 IVS-I-6 / IVS-I-6   x-/- αα/αα 12 M 0.75 8.1 7.1 3.3 
13 IVS-I-6 / IVS-I-6   x-/- αα/αα 22 M 8 9.2 6.2 17.1 
14 IVS-I-6 / IVS-I-6   x-/- αα/αα 18 M 1 10 7.9 9.7 
15 IVS-I-6 / IVS-I-6   x-/- αα/αα 10 F 1 7.8 5.3 4.3 
16 IVS-I-6 / IVS-I-6   x-/- αα/αα 71 M 25 7.1 7.3 2.3 
17 IVS-I-6 / IVS-I-6   x-/- αα/αα 4 M 0.66 8.9 3.8 6.9 
18 IVS-I-6 / IVS-I-6   x-/- αα/αα 23 F 0.25 7.6 7.3 5.8 
19 IVS-I-6 / IVS-I-6   x-/- αα/αα 4 F 2 6.5 8.1 15.8 
20 IVS-I-6 / IVS-I-6   x-/- αα/αα 20 M 0.08 9.3 8 17.1 
21 IVS-I-6 / IVS-I-6   x-/- αα/αα 25 M 0.5 9.2 7.7 12.3 
22 IVS-I-6 / IVS-I-6   x-/- αα/αα 30 F 3 10.7 7.3 5.1 
23 IVS-I-6 / IVS-I-6   x-/- αα/αα 14 F 2 7.6 2.8 7.6 
24 IVS-I-6 / IVS-I-6   x-/- αα/αα 11 M 5 8.4 5.4 7.9 
25 IVS-I-6 / IVS-I-6   x-/- αα/αα 18 M 2 9.9 5.9 6.1 
26 IVS-I-6 / IVS-I-6   x-/- αα/αα 14 F 2 7.6 7.6 3.4 
27 IVS-I-6 / IVS-I-6   x-/- αα/αα 22 M   8.6 6.3 12.3 
28 IVS-I-6 / IVS-I-6   x-/- αα/αα 37 F 2 7.2 6.1 9.3 
29 IVS-I-6 / IVS-I-6   x-/- αα/αα 54 M 25 9.4 5.9 19.5 
30 IVS-I-6 / IVS-I-6   x-/- αα/αα 27 M 1 8.9 7.4 10.3 
31 IVS-I-6 / IVS-I-6   x-/- αα/αα 18 M 5 8.3 7.5 10.1 
32 IVS-I-6 / IVS-I-6   x-/- αα/αα 14 F 0.08 9.5 5.8 10.6 
33 IVS-I-6 / IVS-I-6   x-/- αα/αα 17 M 3 6.4 7.4 8.6 
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34 IVS-I-6 / IVS-I-6   x-/- αα/αα 23 M 12 11.1 6.6 6 
35 IVS-I-6 / IVS-I-6   x-/- αα/αα 34 M 0.08 7.6 6.7 13.6 
36 IVS-I-6 / IVS-I-6   x-/- αα/αα 18 F 1 9 4.6 10 
37 IVS-I-6 / IVS-I-6   x-/- αα/αα 21 F 0.75 9 4.3 24.7 
38 IVS-I-6 / IVS-I-6   x-/- αα/αα 20 M 0.5 8.4 7.3 7.8 
39 IVS-I-6 / IVS-I-
110 
x-/- α2-IVSI-
5nt  
10 F 3 8.7 ND ND 
40 Beta -101/-101 X-/- αα/αα 13 M 5 13.9 4.6 7.4 
41 IVS-II-I /IVS-II-
I 
x+/+ αα/αα 16 M 6 7.7 2.3 68 
42 IVS-II-I /IVS-II-
I  
x+/+ αα/αα 29 M 3 9.8 2.3 83 
43 IVS-II-I /IVS-II-
I  
x+/+ αα/αα 16 F 5 8.6 1.8 67 
44 IVS-I-110 /IVS-
I-110  
x-/- –α3.7/αα  7 F 0.6 9 3.3 1.7 
45 IVS-I-110 /IVS-
I-110 
x-/- αα/αα 4 F 1 11.7 3.2 6.4 
46 IVS-I-110 /IVS-
I-110 
x-/- αα/αα 22 M 3 9.5 8.5 17 
47 IVS-I-I / βA x-/- αα/ααα 20 F 4 NA 3.8 6.3 
48 IVS-II-I G>A / 
IVS-II -848 
x+/- –α3.7/αα  38 F 6 7.1 3 49.1 
49 IVS-I-110 / 
Codon 37 
TGG>TGA 
x-/- αα/αα 24 F 11 6.5 2.5 30.9 
50 IVS-I-I / Codon 
37 Trp>Stop 
x-/- α2-IVSI-
5nt  
39 F 1 8.7 2.9 46.8 
51 IVS-I-6 / Codon 
37 TGG>TGA  
x-/- αα/αα 11 M 1 6.9 3.3 6.6 
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  بحثية استبانة
 (مقابمة مع المرضى)
 في الضفة الغربية، فمسطين عنوان الدراسة: توصيف مرضى التلاسيميا المتوسطة
 
نوع بيتا ىي مرض وراثي ناتج عن خمل كمي في تصنيع خضاب الدم، وتقسم سريريا حسب شدة المرض –التلاسيميا 
حيث يحمل الشخص المورثة المسؤولة عن المرض ولكن لاتظير عميو  :الى ثلاثة أقسام. صفة التلاسيميا نوع بيتا
وتظير عمى المريض اعراض متوسطة الشدة وتختمف شدتيا من  :نوع بيتا –أعراض المرض. التلاسيميا المتوسطة 
 :انوع بيت–شخص لآخر ويحتاج المريض الى علاج عمى شكل نقل دم عمى فترات متباعدة. وأخيرا التلاسيميا الرئيسة 
حيث يعتمد المريض بشكل أساسي ودائم عمى نقل الدم. وعادة يحدث تداخل في تشخيص مرضى التلاسيميا 
لاسيميا رئيسية وبالتالي الثالى تشخيص التلاسيميا المتوسطة كالمتوسطة والرئيسية لصالح الرئيسية مما يؤدي 
ومع تكرار نقل الدم بشكل كبير يعاني  اخضاعيم بشكل غير مبرر طبيا الى نقل دم زائد مما يؤثر سمبا عمييم
 التلاسيميا الرئيسية ونقل الدم.  تقترب من مضاعفات المرضى من مضاعفات
وتيدف الدراسة الى تحديد مرضى التلاسيميا المشخصين او المصنفين "مرضى تلاسيميا متوسطة" ومن ثم إعادة 
) والترحيل الكيربائي CBCالدم الكامل ( تشخيص المرضى باجراء الفحوصات المخبرية الضرورية مثل تعداد
) لموصول الى تشخيص sisylana AND) ومن ثم تحميل المادة الوراثية (siserohportcele bHلخضاب الدم (
نيائي ودقيق مما يتيح ليم الحصول عمى العلاج المناسب، اضافة الى التعرف عمى نوع الطفرات التي تسبب 
 مما يسيل تطوير بروتوكول علاجي وتشخيصي ليؤلاء المرض في المستقبل. التلاسيميا المتوسطة في فمسطين 
ولذلك نرجو من حضرتك التعاون معنا من خلال المشاركة في ىذه الدراسة (وفي حالة كون المريض طفلا نرجو 
اضافة الى التوقيع السماح ليا أو لو بالمشاركة). وتشمل المشاركة الاجابة عن الاسئمة المرفقة ادناه والتبرع بعينة دم، 
عمى طمب المشاركة في الدراسة. عمما ان ىذه الدراسة تتم بالتعاون بين جامعة القدس وجمعية أصدقاء مرضى 
 التلاسيميا.
ونؤكد ان المعمومات التي سوف تقدميا لمدراسة وعينة الدم التي سوف تتبرع بيا سوف تستعمل لأغراض البحث 
 بسرية تامة. العممي فقط وسوف يتم التعامل معيا
 
دس جامعة الق –الباحثة: راشيل فرعون 
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 أسئمة الاستبانة
 عنوان الدراسة: توصيف مرضى التلاسيميا المتوسطة في الضفة الغربية، فمسطين
  اسم المريض
 ذكر □انثى      □ الجنس
  مكان الاقامة
  عمر المريض
  التلاسيمياأو نوع تشخيص 
  عمر المريض عند أول تشخيص
  تاريخ أول عممية نقل دم
  تاريخ آخر عممية نقل دم
  عدد مرات نقل الدم في السنة الأخيرة
  ىل تعاني من تضخم في الطحال حاليا
  ىل أجريت عممية استئصال لمطحال؟ وفي أي عمر؟
  ىل سبق وأجريت عمميات جراحية؟ يرجى تحديدىا
  وجدت)؟ىل تعاني من أمراض مزمنة (يرجى التحيدي ان 
ىل تعاني من زيادة في تجمط الدم أو حدث لك مضاعفات نتيجة تجمط 
 الدم (يرجى التحديد ان وجدت وتحديد عدد المرات وتاريخ آخر مرة):
 
  ىل الاب والام اقارب
  ىل يحمل أحد والديك صفة مرض التلاسيميا نوع بيتا
ىل تأخذ ادوية لمتخمص من الحديد في الجسم 
 )؟ edajxEأو  larefseD(يرجى تحديد النوع 
 
  ومتى بدأت تناول أدوية التخمص من الحديد؟
  ) في آخر مرة تم قياسيا؟lm/gnفي الدم ( nitirreF معدل الفريتين
  )Ld/gm(  bHمعدل الييموغموبين  
  طول المريض (سم)؟
  وزن المريض (كغم)؟
ىل ترغب بالحصول عمى نتيجة التحاليل لعينة الدم التي تتبرع بيا 
 اليوم (يرجى تحديد طريقة التواصل مثل بريد الكتروني أو فاكس)؟
 
  ىل ترغب باضافة معمومات أخرى؟
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 اقرار بالمشاركة في الدراسة
 
المريض طفلا اسمح ليا او لو بالمشاركة) في الدراسة بعنوان:  نانا الموقع ادناه أقر بالمشاركة (وفي حال كا
. عمما انو تم اطلاعي عمى اليدف من توصيف مرضى التلاسيميا المتوسطة في الضفة الغربية، فمسطين
وان المعمومات التي قدمتيا لمدراسة وعينة الدم التي تبرعت بيا سوف يتم استخداميا لأغراض البحث  الدراسة
 .العممي فقط
 
 اسم المريض: 
 
 : التوقيع
 
 التاريخ: 
 
 ------انتيى الاقرار  ---
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 فمسطين -التوصيف الجزيئي لمبيتا ثلاسيميا المتوسطة في الضفة الغربية
 إعداد: رشيل ابراهيم حسن فرعون
 محمود عبد الرحمن سرور الدكتورالمشرف: 
 الممخص:
 220فً العالم كما فً فلسطٌن.  هناك أكثر من  انتشارا الوراثةالثلاسٌمٌا هً اكثر الاضطرابات المتنحٌة 
طفرات وراثٌة مسؤولة عن انخفاض إنتاج سلسلة البٌتا جلوبٌن.  البٌتا ثلاسٌمٌا الوسطى تقع بٌن الثلاسٌمٌا 
العظمى التً تعتمد على النقل المستمر للدم والثلاسٌمٌا الصغرى التً لا تعتمد على نقل الدم.  تظهر 
لاسٌمٌا المتوسطة بصورة سرٌرٌة متغٌرة  بحد كبٌر تتراوح بٌن خفٌفة إلى شدٌدة فقر الدم التً تتطلب الث
نقل الدم فً بعض الأحٌان.  وراثٌا هً  مجموعة غٌر متجانسة تعزى إلى الطفرات فً البٌتا جٌن وحدها 
ما.  قد تكون المحددات الوراثٌة أو المٌراث المشترك لطفرات البٌتا  وجٌنات  أخرى مثل جٌنات الألفا والجا
للثلاسٌمٌا المتوسطة مختلفة فً مناطق مختلفة، ولا سٌما فً المجموعات العرقٌة المختلفة وتتأثر أنواع 
مختلفة من الألائل الثلاسٌمٌا المشتركة فً كل منطقة والمجموعة العرقٌة. الهدف من الدراسة هو  تحدٌد 
لمرضى الثلاسٌمٌا المتوسطة بمنطقة الضفة الغربٌة فً فلسطٌن، وكذلك طٌف جٌنات البٌتا والألفا والجاما 
حالة ثلاسٌمٌا متوسطة, حٌث تم تقٌٌم فحص عد  51لتقٌٌم الممارسات الإدارٌة لهؤلاء المرضى.  تم تسجٌل 
-((فا الدم الكامل والترحٌل الكهربائً لخضاب الدم.  ومن ثم تحلٌل المادة الوراثٌة لكل من جٌن البٌتا, الأل
, بإستخدام عدة طرق للكشف عن )I nmX(والجاما  led tn 5-1 ISVI-2α3itnaααα ,DEM-- ,2.4α- ,7.3α
 . SMRA ,gnicneuqes AND ,RCP-paGهذه الطفرات وهً 
 011-I-SVI ,T>C 6- I-SVIلوحظت سبع طفرات جٌنٌة  للبٌتا  بٌن مرضى الثلاسٌمٌا المتوسطة 
 848-II-SVI,  101- B ,potS>prT 73 nodoC ,A>G 1-I-SVI ,A>G 1-II-SVI ,A>G
لحالات  وهً الأكثر شٌوعا  T>C 6-I-SVIأنماط وراثٌة ، المتماثلة منها   25. وقد لوحظت A>C
 011-I-SVI%.  النمط الوراثً الثانً المشترك بٌن المرضى هو  1..5الثلاسٌمٌا المتوسطة بنسبة 
أنماط  باقً السبع  %. اما 8.5التً شكلت  A>G 1-II-SVI% , والطفرة  8.5والذي شكل نسبة  A>G
% وهً من  9.8% من المرضى. طفرات الألفا شوهدت فً خمس مرضى فقط بنسبة  0فشكلت  وراثٌة
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.  طفرات الجاما ظهرت فً اربعة مرضى, ثلاثة منهم )led tn 5-1 ISVI-2α3itnaααα ,7.3α-(انواع 
هً العامل  T>C 6- I-SVIمتماثلة الوراثة وواحدة متغاٌرة الوراثة.  وراثة العامل المتماثل المعتدل 
الرئٌسً فً النمط الظاهري للثلاسٌمٌا المتوسطة فً الضفة الغربٌة.  طفرات الألفا والجاما ساعدت على 
 للثلاسٌمٌا فً عدد قلٌل من المرضى. تحفٌز النمط الظاهري 
هو النمط الاكثر شٌوعا بٌن المرضى فً فلسطٌن.  T>C 6- I-SVIوفً الخلاصة وراثة  العامل المتماثل 
المتماثلة وجدت فً مرٌض واحد تسجل للمرة الاولى فً فلسطٌن.  نتائج الدراسة  B-T>C 101طفرة 
لاسٌما المتوسطة فً فلسطٌن وتوفر المزٌد من البٌانات عن ستؤثر إٌجابٌا على الإدارة الصحٌة لمرضى الث
 .المنشأ والتوزٌع لطفرات البٌتا
 
 
